<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Botulinum Toxin Manufacturing Guide</title>
    <style>
        body {
            font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
            line-height: 1.6;
            max-width: 800px;
            margin: 0 auto;
            padding: 20px;
            background-color: #f5f5f5;
        }
        .container {
            background-color: white;
            padding: 30px;
            border-radius: 8px;
            box-shadow: 0 2px 4px rgba(0,0,0,0.1);
        }
        .content {
            white-space: pre-wrap;
            word-wrap: break-word;
        }
        .metadata {
            display: none;
        }
    </style>
</head>
<body>
    <div class="container">
        <div class="content">WO2015016462A1 - Method for production of botulinum toxin - Google Patents Method for production of botulinum toxin Download PDF Info Publication number WO2015016462A1 WO2015016462A1 PCT/KR2014/004003 KR2014004003W WO2015016462A1 WO 2015016462 A1 WO2015016462 A1 WO 2015016462A1 KR 2014004003 W KR2014004003 W KR 2014004003W WO 2015016462 A1 WO2015016462 A1 WO 2015016462A1 Authority WO WIPO (PCT) Prior art keywords botulinum toxin botulinum toxin precipitate anion exchange Prior art date 2013-08-02 Application number PCT/KR2014/004003 Other languages French ( fr ) Inventor Chung Sei Kim Kwan Young Song Kyoung Min Min Yeong Duk An Original Assignee Daewoong Co., Ltd. Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) 2013-08-02 Filing date 2014-05-07 Publication date 2015-02-05 Family has litigation First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49987856&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2015016462(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License. 2014-05-07 Priority to SG11201509486VA priority Critical patent/SG11201509486VA/en 2014-05-07 Priority to BR112015029973-3A priority patent/BR112015029973B1/en 2014-05-07 Priority to CN201480012202.6A priority patent/CN105392795B/en 2014-05-07 Priority to MX2015016481A priority patent/MX362821B/en 2014-05-07 Priority to NO14832966A priority patent/NO2920199T3/no 2014-05-07 Priority to SI201430702T priority patent/SI2920199T1/en 2014-05-07 Priority to EP14832966.7A priority patent/EP2920199B1/en 2014-05-07 Priority to RU2015151186A priority patent/RU2627159C2/en 2014-05-07 Application filed by Daewoong Co., Ltd. filed Critical Daewoong Co., Ltd. 2014-05-07 Priority to CA2912553A priority patent/CA2912553C/en 2014-05-07 Priority to ES14832966.7T priority patent/ES2665288T3/en 2014-05-07 Priority to LTEP14832966.7T priority patent/LT2920199T/en 2014-05-07 Priority to HRP20180679TT priority patent/HRP20180679T1/en 2014-05-07 Priority to DK14832966.7T priority patent/DK2920199T3/en 2014-05-07 Priority to JP2016506267A priority patent/JP6307150B2/en 2014-05-07 Priority to HK16103705.2A priority patent/HK1215715B/en 2014-05-07 Priority to PL14832966T priority patent/PL2920199T3/en 2014-05-07 Priority to AU2014297167A priority patent/AU2014297167B2/en 2014-05-07 Priority to US14/654,819 priority patent/US9512418B2/en 2015-02-05 Publication of WO2015016462A1 publication Critical patent/WO2015016462A1/en 2015-08-24 Priority to PH12015501855A priority patent/PH12015501855A1/en 2015-11-29 Priority to SA515370208A priority patent/SA515370208B1/en 2018-04-26 Priority to CY20181100439T priority patent/CY1120410T1/en Links Espacenet Global Dossier PatentScope Discuss 108030001720 Bontoxilysin Proteins 0.000 title claims abstract description 174 229940053031 botulinum toxin Drugs 0.000 title claims abstract description 164 238000004519 manufacturing process Methods 0.000 title claims abstract description 17 238000000034 method Methods 0.000 claims abstract description 70 108700012359 toxins Proteins 0.000 claims abstract description 53 238000005571 anion exchange chromatography Methods 0.000 claims abstract description 40 239000002244 precipitate Substances 0.000 claims abstract description 27 239000000872 buffer Substances 0.000 claims abstract description 20 239000002253 acid Substances 0.000 claims abstract description 16 101710163270 Nuclease Proteins 0.000 claims abstract description 9 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims abstract description 7 239000000137 peptide hydrolase inhibitor Substances 0.000 claims abstract description 7 VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 30 QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 20 241000193155 Clostridium botulinum Species 0.000 claims description 17 BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 16 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 16 235000011130 ammonium sulphate Nutrition 0.000 claims description 15 238000003916 acid precipitation Methods 0.000 claims description 10 239000012064 sodium phosphate buffer Substances 0.000 claims description 8 238000000605 extraction Methods 0.000 claims description 5 102000016911 Deoxyribonucleases Human genes 0.000 claims description 4 108010053770 Deoxyribonucleases Proteins 0.000 claims description 4 102000006382 Ribonucleases Human genes 0.000 claims description 4 108010083644 Ribonucleases Proteins 0.000 claims description 4 LZCZIHQBSCVGRD-UHFFFAOYSA-N benzenecarboximidamide;hydron;chloride Chemical compound [Cl-].NC(=[NH2+])C1=CC=CC=C1 LZCZIHQBSCVGRD-UHFFFAOYSA-N 0.000 claims description 3 231100000765 toxin Toxicity 0.000 abstract description 35 239000003053 toxin Substances 0.000 abstract description 35 230000000694 effects Effects 0.000 abstract description 12 230000008569 process Effects 0.000 abstract description 11 238000007796 conventional method Methods 0.000 abstract description 7 206010008129 cerebral palsy Diseases 0.000 abstract description 5 230000002829 reductive effect Effects 0.000 abstract description 5 230000001839 systemic circulation Effects 0.000 abstract description 5 206010019468 Hemiplegia Diseases 0.000 abstract description 4 208000018360 neuromuscular disease Diseases 0.000 abstract description 4 201000007770 spastic cerebral palsy Diseases 0.000 abstract description 4 201000008417 spastic hemiplegia Diseases 0.000 abstract description 4 230000037303 wrinkles Effects 0.000 abstract description 4 238000002360 preparation method Methods 0.000 abstract description 3 108010048262 DWP450 Proteins 0.000 description 43 210000003205 muscle Anatomy 0.000 description 32 FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 25 102000004169 proteins and genes Human genes 0.000 description 22 108090000623 proteins and genes Proteins 0.000 description 22 235000018102 proteins Nutrition 0.000 description 21 101710117542 Botulinum neurotoxin type A Proteins 0.000 description 16 XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 16 229940089093 botox Drugs 0.000 description 16 229960004716 idoxuridine Drugs 0.000 description 16 239000012535 impurity Substances 0.000 description 15 239000011780 sodium chloride Substances 0.000 description 15 238000000746 purification Methods 0.000 description 14 238000001556 precipitation Methods 0.000 description 13 239000000463 material Substances 0.000 description 12 239000008194 pharmaceutical composition Substances 0.000 description 10 HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9 239000003957 anion exchange resin Substances 0.000 description 9 239000000203 mixture Substances 0.000 description 9 239000004480 active ingredient Substances 0.000 description 7 238000007792 addition Methods 0.000 description 7 238000004587 chromatography analysis Methods 0.000 description 7 239000007788 liquid Substances 0.000 description 7 230000001769 paralizing effect Effects 0.000 description 7 238000011218 seed culture Methods 0.000 description 7 239000006228 supernatant Substances 0.000 description 7 102000008100 Human Serum Albumin Human genes 0.000 description 6 108091006905 Human Serum Albumin Proteins 0.000 description 6 241000700159 Rattus Species 0.000 description 6 230000000052 comparative effect Effects 0.000 description 6 230000007423 decrease Effects 0.000 description 6 239000002581 neurotoxin Substances 0.000 description 6 231100000618 neurotoxin Toxicity 0.000 description 6 239000007924 injection Substances 0.000 description 5 238000002347 injection Methods 0.000 description 5 231100000062 no-observed-adverse-effect level Toxicity 0.000 description 5 238000011084 recovery Methods 0.000 description 5 239000000243 solution Substances 0.000 description 5 238000012453 sprague-dawley rat model Methods 0.000 description 5 238000012360 testing method Methods 0.000 description 5 231100000419 toxicity Toxicity 0.000 description 5 230000001988 toxicity Effects 0.000 description 5 241000894006 Bacteria Species 0.000 description 4 101710154606 Hemagglutinin Proteins 0.000 description 4 101710138657 Neurotoxin Proteins 0.000 description 4 101710093908 Outer capsid protein VP4 Proteins 0.000 description 4 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 4 101710176177 Protein A56 Proteins 0.000 description 4 206010040954 Skin wrinkling Diseases 0.000 description 4 MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 4 230000036982 action potential Effects 0.000 description 4 210000004027 cell Anatomy 0.000 description 4 150000001875 compounds Chemical class 0.000 description 4 238000002425 crystallisation Methods 0.000 description 4 230000008025 crystallization Effects 0.000 description 4 238000002474 experimental method Methods 0.000 description 4 238000001914 filtration Methods 0.000 description 4 238000009472 formulation Methods 0.000 description 4 231100000252 nontoxic Toxicity 0.000 description 4 230000003000 nontoxic effect Effects 0.000 description 4 239000000546 pharmaceutical excipient Substances 0.000 description 4 102100028188 Cystatin-F Human genes 0.000 description 3 101710169749 Cystatin-F Proteins 0.000 description 3 102000004190 Enzymes Human genes 0.000 description 3 108090000790 Enzymes Proteins 0.000 description 3 GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3 108091005804 Peptidases Proteins 0.000 description 3 239000004365 Protease Substances 0.000 description 3 238000012258 culturing Methods 0.000 description 3 238000000502 dialysis Methods 0.000 description 3 230000002255 enzymatic effect Effects 0.000 description 3 238000012869 ethanol precipitation Methods 0.000 description 3 239000000284 extract Substances 0.000 description 3 238000004128 high performance liquid chromatography Methods 0.000 description 3 239000004615 ingredient Substances 0.000 description 3 238000004255 ion exchange chromatography Methods 0.000 description 3 239000008101 lactose Substances 0.000 description 3 230000001376 precipitating effect Effects 0.000 description 3 238000001542 size-exclusion chromatography Methods 0.000 description 3 239000001488 sodium phosphate Substances 0.000 description 3 229910000162 sodium phosphate Inorganic materials 0.000 description 3 238000001179 sorption measurement Methods 0.000 description 3 238000003860 storage Methods 0.000 description 3 RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3 NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2 VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 2 IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2 241000193464 Clostridium sp. Species 0.000 description 2 208000014094 Dystonic disease Diseases 0.000 description 2 WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2 208000008454 Hyperhidrosis Diseases 0.000 description 2 241000699670 Mus sp. Species 0.000 description 2 108010010469 Qa-SNARE Proteins Proteins 0.000 description 2 108010005730 R-SNARE Proteins Proteins 0.000 description 2 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2 CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2 229930006000 Sucrose Natural products 0.000 description 2 102000002215 Synaptobrevin Human genes 0.000 description 2 102000050389 Syntaxin Human genes 0.000 description 2 238000012870 ammonium sulfate precipitation Methods 0.000 description 2 238000004458 analytical method Methods 0.000 description 2 230000008901 benefit Effects 0.000 description 2 231100001103 botulinum neurotoxin Toxicity 0.000 description 2 229940041514 candida albicans extract Drugs 0.000 description 2 239000013622 capto Q Substances 0.000 description 2 108010079058 casein hydrolysate Proteins 0.000 description 2 239000003795 chemical substances by application Substances 0.000 description 2 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2 239000012149 elution buffer Substances 0.000 description 2 238000011156 evaluation Methods 0.000 description 2 230000028023 exocytosis Effects 0.000 description 2 238000000855 fermentation Methods 0.000 description 2 230000004151 fermentation Effects 0.000 description 2 238000004108 freeze drying Methods 0.000 description 2 239000008103 glucose Substances 0.000 description 2 239000000185 hemagglutinin Substances 0.000 description 2 238000011081 inoculation Methods 0.000 description 2 239000007928 intraperitoneal injection Substances 0.000 description 2 238000005342 ion exchange Methods 0.000 description 2 239000003456 ion exchange resin Substances 0.000 description 2 229920003303 ion-exchange polymer Polymers 0.000 description 2 230000002147 killing effect Effects 0.000 description 2 239000008188 pellet Substances 0.000 description 2 239000008363 phosphate buffer Substances 0.000 description 2 229920001184 polypeptide Polymers 0.000 description 2 102000004196 processed proteins & peptides Human genes 0.000 description 2 108090000765 processed proteins & peptides Proteins 0.000 description 2 125000001453 quaternary ammonium group Chemical group 0.000 description 2 239000011347 resin Substances 0.000 description 2 229920005989 resin Polymers 0.000 description 2 238000005185 salting out Methods 0.000 description 2 150000003839 salts Chemical class 0.000 description 2 230000000638 stimulation Effects 0.000 description 2 239000000758 substrate Substances 0.000 description 2 239000005720 sucrose Substances 0.000 description 2 XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2 239000012138 yeast extract Substances 0.000 description 2 HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1 UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1 DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1 241000270728 Alligator Species 0.000 description 1 GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1 206010002153 Anal fissure Diseases 0.000 description 1 206010059237 Auriculotemporal syndrome Diseases 0.000 description 1 241000193738 Bacillus anthracis Species 0.000 description 1 206010064888 Cervicogenic headache Diseases 0.000 description 1 241001112695 Clostridiales Species 0.000 description 1 241000193403 Clostridium Species 0.000 description 1 102000008186 Collagen Human genes 0.000 description 1 108010035532 Collagen Proteins 0.000 description 1 208000000289 Esophageal Achalasia Diseases 0.000 description 1 206010063006 Facial spasm Diseases 0.000 description 1 208000001640 Fibromyalgia Diseases 0.000 description 1 208000018522 Gastrointestinal disease Diseases 0.000 description 1 108010010803 Gelatin Proteins 0.000 description 1 208000004041 Gustatory Sweating Diseases 0.000 description 1 206010019233 Headaches Diseases 0.000 description 1 208000004095 Hemifacial Spasm Diseases 0.000 description 1 229920001612 Hydroxyethyl starch Polymers 0.000 description 1 208000037147 Hypercalcaemia Diseases 0.000 description 1 206010020853 Hypertonic bladder Diseases 0.000 description 1 DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1 108010006035 Metalloproteases Proteins 0.000 description 1 102000005741 Metalloproteases Human genes 0.000 description 1 208000019695 Migraine disease Diseases 0.000 description 1 208000007101 Muscle Cramp Diseases 0.000 description 1 208000008238 Muscle Spasticity Diseases 0.000 description 1 206010062575 Muscle contracture Diseases 0.000 description 1 206010028391 Musculoskeletal Pain Diseases 0.000 description 1 208000002033 Myoclonus Diseases 0.000 description 1 NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1 AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1 206010030136 Oesophageal achalasia Diseases 0.000 description 1 208000009722 Overactive Urinary Bladder Diseases 0.000 description 1 208000002193 Pain Diseases 0.000 description 1 206010033645 Pancreatitis Diseases 0.000 description 1 102000035195 Peptidases Human genes 0.000 description 1 206010034650 Peritoneal adhesions Diseases 0.000 description 1 206010036313 Post-traumatic headache Diseases 0.000 description 1 239000012564 Q sepharose fast flow resin Substances 0.000 description 1 208000003782 Raynaud disease Diseases 0.000 description 1 208000012322 Raynaud phenomenon Diseases 0.000 description 1 208000036071 Rhinorrhea Diseases 0.000 description 1 206010039101 Rhinorrhoea Diseases 0.000 description 1 206010039424 Salivary hypersecretion Diseases 0.000 description 1 229920005654 Sephadex Polymers 0.000 description 1 239000012507 Sephadex™ Substances 0.000 description 1 229920002684 Sepharose Polymers 0.000 description 1 208000008630 Sialorrhea Diseases 0.000 description 1 206010040744 Sinus headache Diseases 0.000 description 1 206010040925 Skin striae Diseases 0.000 description 1 208000005392 Spasm Diseases 0.000 description 1 206010067672 Spasmodic dysphonia Diseases 0.000 description 1 208000004350 Strabismus Diseases 0.000 description 1 208000031439 Striae Distensae Diseases 0.000 description 1 208000001871 Tachycardia Diseases 0.000 description 1 206010043269 Tension headache Diseases 0.000 description 1 208000008548 Tension-Type Headache Diseases 0.000 description 1 208000024799 Thyroid disease Diseases 0.000 description 1 206010044074 Torticollis Diseases 0.000 description 1 HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1 206010044565 Tremor Diseases 0.000 description 1 102000004142 Trypsin Human genes 0.000 description 1 108090000631 Trypsin Proteins 0.000 description 1 108010057266 Type A Botulinum Toxins Proteins 0.000 description 1 206010046543 Urinary incontinence Diseases 0.000 description 1 206010046555 Urinary retention Diseases 0.000 description 1 241000700647 Variola virus Species 0.000 description 1 206010047163 Vasospasm Diseases 0.000 description 1 208000013142 Writer cramp Diseases 0.000 description 1 241000607479 Yersinia pestis Species 0.000 description 1 210000001015 abdomen Anatomy 0.000 description 1 108010079650 abobotulinumtoxinA Proteins 0.000 description 1 OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1 229960004373 acetylcholine Drugs 0.000 description 1 201000000621 achalasia Diseases 0.000 description 1 230000009471 action Effects 0.000 description 1 230000002411 adverse Effects 0.000 description 1 238000013019 agitation Methods 0.000 description 1 HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1 238000000540 analysis of variance Methods 0.000 description 1 238000005349 anion exchange Methods 0.000 description 1 150000001450 anions Chemical class 0.000 description 1 239000007864 aqueous solution Substances 0.000 description 1 230000002917 arthritic effect Effects 0.000 description 1 206010003549 asthenia Diseases 0.000 description 1 230000036617 axillary hyperhidrosis Effects 0.000 description 1 210000003050 axon Anatomy 0.000 description 1 229940065181 bacillus anthracis Drugs 0.000 description 1 206010005159 blepharospasm Diseases 0.000 description 1 230000000744 blepharospasm Effects 0.000 description 1 208000003295 carpal tunnel syndrome Diseases 0.000 description 1 230000015556 catabolic process Effects 0.000 description 1 238000005277 cation exchange chromatography Methods 0.000 description 1 150000001768 cations Chemical group 0.000 description 1 238000005119 centrifugation Methods 0.000 description 1 201000002866 cervical dystonia Diseases 0.000 description 1 230000008859 change Effects 0.000 description 1 238000012512 characterization method Methods 0.000 description 1 230000001713 cholinergic effect Effects 0.000 description 1 239000007979 citrate buffer Substances 0.000 description 1 238000005345 coagulation Methods 0.000 description 1 230000015271 coagulation Effects 0.000 description 1 229920001436 collagen Polymers 0.000 description 1 239000013065 commercial product Substances 0.000 description 1 208000006111 contracture Diseases 0.000 description 1 239000002537 cosmetic Substances 0.000 description 1 238000006731 degradation reaction Methods 0.000 description 1 239000003599 detergent Substances 0.000 description 1 201000003892 detrusor sphincter dyssynergia Diseases 0.000 description 1 206010012601 diabetes mellitus Diseases 0.000 description 1 201000010099 disease Diseases 0.000 description 1 OKBPCTLSPGDQBO-UHFFFAOYSA-L disodium;dichloride Chemical group [Na+].[Na+].[Cl-].[Cl-] OKBPCTLSPGDQBO-UHFFFAOYSA-L 0.000 description 1 208000035475 disorder Diseases 0.000 description 1 238000004090 dissolution Methods 0.000 description 1 229940098753 dysport Drugs 0.000 description 1 238000004520 electroporation Methods 0.000 description 1 206010015037 epilepsy Diseases 0.000 description 1 238000011067 equilibration Methods 0.000 description 1 230000001815 facial effect Effects 0.000 description 1 201000002904 focal dystonia Diseases 0.000 description 1 201000002865 focal hand dystonia Diseases 0.000 description 1 239000000499 gel Substances 0.000 description 1 238000001641 gel filtration chromatography Methods 0.000 description 1 239000008273 gelatin Substances 0.000 description 1 229920000159 gelatin Polymers 0.000 description 1 235000019322 gelatine Nutrition 0.000 description 1 235000011852 gelatine desserts Nutrition 0.000 description 1 150000004676 glycans Chemical class 0.000 description 1 230000005484 gravity Effects 0.000 description 1 210000000527 greater trochanter Anatomy 0.000 description 1 238000003306 harvesting Methods 0.000 description 1 IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1 231100000869 headache Toxicity 0.000 description 1 231100000171 higher toxicity Toxicity 0.000 description 1 230000002209 hydrophobic effect Effects 0.000 description 1 229940050526 hydroxyethylstarch Drugs 0.000 description 1 230000000148 hypercalcaemia Effects 0.000 description 1 208000030915 hypercalcemia disease Diseases 0.000 description 1 230000001660 hyperkinetic effect Effects 0.000 description 1 239000007943 implant Substances 0.000 description 1 230000002401 inhibitory effect Effects 0.000 description 1 229940102223 injectable solution Drugs 0.000 description 1 238000003780 insertion Methods 0.000 description 1 230000037431 insertion Effects 0.000 description 1 210000000936 intestine Anatomy 0.000 description 1 230000003834 intracellular effect Effects 0.000 description 1 239000007927 intramuscular injection Substances 0.000 description 1 238000010255 intramuscular injection Methods 0.000 description 1 150000002500 ions Chemical class 0.000 description 1 239000007951 isotonicity adjuster Substances 0.000 description 1 230000000366 juvenile effect Effects 0.000 description 1 229960004184 ketamine hydrochloride Drugs 0.000 description 1 210000004717 laryngeal muscle Anatomy 0.000 description 1 230000000670 limiting effect Effects 0.000 description 1 239000013028 medium composition Substances 0.000 description 1 206010027599 migraine Diseases 0.000 description 1 210000000715 neuromuscular junction Anatomy 0.000 description 1 231100000189 neurotoxic Toxicity 0.000 description 1 230000002887 neurotoxic effect Effects 0.000 description 1 239000002858 neurotransmitter agent Substances 0.000 description 1 229910052757 nitrogen Inorganic materials 0.000 description 1 WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1 208000020629 overactive bladder Diseases 0.000 description 1 230000037392 palmar hyperhidrosis Effects 0.000 description 1 230000035699 permeability Effects 0.000 description 1 230000000144 pharmacologic effect Effects 0.000 description 1 230000036563 plantar hyperhidrosis Effects 0.000 description 1 229920001282 polysaccharide Polymers 0.000 description 1 239000005017 polysaccharide Substances 0.000 description 1 239000001267 polyvinylpyrrolidone Substances 0.000 description 1 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1 239000003755 preservative agent Substances 0.000 description 1 230000002335 preservative effect Effects 0.000 description 1 230000002265 prevention Effects 0.000 description 1 239000000047 product Substances 0.000 description 1 201000007094 prostatitis Diseases 0.000 description 1 208000037803 restenosis Diseases 0.000 description 1 230000028327 secretion Effects 0.000 description 1 238000000926 separation method Methods 0.000 description 1 230000000405 serological effect Effects 0.000 description 1 210000002027 skeletal muscle Anatomy 0.000 description 1 208000017520 skin disease Diseases 0.000 description 1 210000002460 smooth muscle Anatomy 0.000 description 1 239000011734 sodium Substances 0.000 description 1 229910052708 sodium Inorganic materials 0.000 description 1 229940074404 sodium succinate Drugs 0.000 description 1 ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1 239000007787 solid Substances 0.000 description 1 201000002849 spasmodic dystonia Diseases 0.000 description 1 208000018198 spasticity Diseases 0.000 description 1 241000894007 species Species 0.000 description 1 239000003381 stabilizer Substances 0.000 description 1 230000001954 sterilising effect Effects 0.000 description 1 238000004659 sterilization and disinfection Methods 0.000 description 1 239000007929 subcutaneous injection Substances 0.000 description 1 238000010254 subcutaneous injection Methods 0.000 description 1 230000035900 sweating Effects 0.000 description 1 230000006794 tachycardia Effects 0.000 description 1 210000002435 tendon Anatomy 0.000 description 1 230000001225 therapeutic effect Effects 0.000 description 1 CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 1 210000002303 tibia Anatomy 0.000 description 1 231100000820 toxicity test Toxicity 0.000 description 1 239000012588 trypsin Substances 0.000 description 1 210000000689 upper leg Anatomy 0.000 description 1 238000001291 vacuum drying Methods 0.000 description 1 239000003643 water by type Substances 0.000 description 1 238000005303 weighing Methods 0.000 description 1 230000029663 wound healing Effects 0.000 description 1 Images Classifications C — CHEMISTRY; METALLURGY C12 — BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING C12N — MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA C12N9/00 — Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes C12N9/14 — Hydrolases (3) C12N9/48 — Hydrolases (3) acting on peptide bonds (3.4) C12N9/50 — Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) C12N9/52 — Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea C — CHEMISTRY; METALLURGY C07 — ORGANIC CHEMISTRY C07K — PEPTIDES C07K14/00 — Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof C07K14/195 — Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria C07K14/33 — Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G) C — CHEMISTRY; METALLURGY C07 — ORGANIC CHEMISTRY C07K — PEPTIDES C07K1/00 — General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length C07K1/14 — Extraction; Separation; Purification C07K1/16 — Extraction; Separation; Purification by chromatography C07K1/18 — Ion-exchange chromatography C — CHEMISTRY; METALLURGY C07 — ORGANIC CHEMISTRY C07K — PEPTIDES C07K1/00 — General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length C07K1/14 — Extraction; Separation; Purification C07K1/30 — Extraction; Separation; Purification by precipitation C — CHEMISTRY; METALLURGY C07 — ORGANIC CHEMISTRY C07K — PEPTIDES C07K1/00 — General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length C07K1/14 — Extraction; Separation; Purification C07K1/36 — Extraction; Separation; Purification by a combination of two or more processes of different types C — CHEMISTRY; METALLURGY C12 — BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING C12P — FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE C12P21/00 — Preparation of peptides or proteins C — CHEMISTRY; METALLURGY C12 — BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING C12Y — ENZYMES C12Y304/00 — Hydrolases acting on peptide bonds, i.e. peptidases (3.4) C12Y304/24 — Metalloendopeptidases (3.4.24) C12Y304/24069 — Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin Definitions the present invention relates to a method for production of a botulinum toxin, and more particularly to a method for preparation of botulinum toxin, the method comprising the steps of: (a) treating a culture of a botulinum toxin-producing strain with acid to precipitate a botulinum toxin; (b) adding buffer to the precipitated botulinum toxin, followed by treatment with a protease inhibitor and nuclease, thereby extracting the botulinum toxin; (c) treating the extracted botulinum toxin with acid to precipitate the botulinum toxin and dissolving the precipitate in buffer; and (d) purifying the botulinum toxin by anion exchange chromatography. Clostridium sp. strains that secrete neurotoxins have been discovered since 1890s, and the characterization of toxins that are secreted from these strains has been made for the past 70 years (Schant, E. J. et al., Microbiol. Rev. , 56:80, 1992). Neurotoxins derived from the Clostridium sp. strains that is, botulinum toxins, are classified into seven types (types A to G) depending on their serological properties. Each of the toxins has a toxin protein having a size of about 150 KDa and naturally contains a complex of several non-toxic proteins. a medium complex (300 kDa) is composed of a toxin protein and a non-toxic non-hemagglutinin protein, and a large complex (450 kDa) and a very large complex (900 kDa) are composed of the medium complex bound to hemagglutinin (Sugiyama, H., Microbiol. Rev ., 44: 419, 1980). Such non-toxic hemagglutinin proteins are known to function to protect the toxin from low pH and various proteases in the intestines. the toxin is synthesized as a single polypeptide having a molecular weight of about 150 kDa in cells, and then cleaved at a position of 1/3 starting from the N-terminal end by the action of intracellular protease or treatment with an artificial enzyme such as trypsin into two units: a light chain (L; molecular weight: 50 kDa) and a heavy chain (H; molecular weight: 100 kDa). L molecular weight: 50 kDa H molecular weight: 100 kDa the cleaved toxin has greatly increased toxicity compared to the single polypeptide. the two units are linked to each other by a disulfide bond and have different functions. the heavy chain binds to a receptor of a target cell (Park. the toxin inhibits the exocytosis of acetylcholine at the cholinergic presynapse of a neuromuscular junction to cause asthenia. It has been considered that treatment with a very small amount of the toxin exhibits toxicity, suggesting that the toxin has any enzymatic activity (Simpson, L. L. et al., Ann. Rev. Pharmaeol. Toxicol., 26:427, 1986). the toxin has metallopeptidase activity, and its substrate is composed of synaptobrevin, syntaxin, a synaptosomal associated protein of 25 KDa (SNAP25) or the like, which are the unit proteins of an exocytosis machinery complex. SNAP25 synaptosomal associated protein of 25 KDa Each type of toxin uses one of the above-described three proteins as its substrate, and it is known that type B, D, F and G toxins cleave synaptobrevin at a specific site, type A and E toxins cleave SNAP25 at a specific site, and type C cleaves syntaxin at a specific site (Binz, T. et al., J. Biol. Chem. , 265:9153, 1994). type A botulinum toxin is known to be soluble in a dilute aqueous solution at a pH of 4.0-6.8. It is known that a stable non-toxic protein is separated from neurotoxin at a pH of about 7 or higher, and as a result, the toxicity is gradually lost. Particularly, it is known that the toxicity decreases as pH and temperature increase. the botulinum toxin is fatal to the human body even in small amounts and is easy to produce in large amounts. Thus, it constitutes four major bio-terror weapons together with Bacillus anthracis, Yersinia pestis and smallpox virus. type A botulinum toxin when type A botulinum toxin is injected at a dose that does not systematically affect the human body, it can paralyze local muscle in the injected site. Based on this characteristic, type A botulinum toxin can be used in a wide range of applications, including winkle removing agents, agents for treating spastic hemiplegia and cerebral palsy, etc. the demand for type A botulinum toxin has increased, and studies on methods of producing botulinum toxin so as to satisfy the demand have been actively conducted. a current typical commercial product is BOTOX® (a purified neurotoxin complex of type A botulinum toxin) that is commercially available from Allergan, Inc., USA. a 100-unit vial of BOTOX ® is composed of about 5 ng of a purified neurotoxin complex of type A botulinum toxin, 0.5 mg of human serum albumin and 0.9 mg of sodium chloride and is reconstituted using sterile saline without a preservative (injection of 0.9% sodium chloride). Dysport ® a complex of Clostridium botulinum type A toxin and hemagglutinin, which has lactose and human serum albumin in a pharmaceutical composition containing botulinum toxin and is reconstituted using 0.9% sodium chloride before use Ipsen Ltd., UK MyoBlocTM (an injectable solution (a pH of about 5.6) comprising botulinum type B toxin, human serum albumin, sodium succinate and sodium chloride) that is commercially available from Solstice Neurosciences, Inc. Conventional methods used to produce botulinum toxins include an acid precipitation method, a precipitation method by salt, and a chromatographic method. Japanese Patent Laid-Open Publication No. 1994-192296 discloses a method of producing a crystalline botulinum type A toxin by culturing Clostridium botulinum bacteria, followed by acid precipitation, extraction, addition of nuclease, and crystallization. US Patent No. 5696077 discloses a method of a crystalline botulinum type B toxin by culturing Clostridium botulinum bacteria, followed by acid precipitation, extraction, ion exchange chromatography, gel filtration chromatography and crystallization. Simpson et al. produced a botulinum type A toxin by purifying botulinum neurotoxin by gravity flow chromatography, followed by HPLC, capture using affinity resin, size exclusion chromatography, and ion (anion and cation) exchange chromatography including the use of two different ion exchange columns ( Method in Enzymology , 165:76, 1988), and Wang et al. used precipitation and ion chromatography to purify a botulinum type A toxin ( Dermatol Las Faci Cosm Surg ., 2002:58, 2002). US Patent No. 6818409 discloses the use of ion exchange and lactose columns to purify a botulinum toxin US Patent No. 7452697 discloses a botulinum type A toxin by ion exchange chromatography and hydrophobic chromatography Korean Patent Laid-Open Publication No. 2009-0091501 discloses a method of purifying a botulinum toxin by acid precipitation and anion exchange chromatography US Publication No. 2013-0156756 discloses a method of purifying a botulinum toxin by anion exchange chromatography and cation exchange chromatography. the conventional methods have problems in that the use of anion exchange chromatography adversely affects the gel banding pattern of botulinum toxins (US Patent No. 7452697) and in that these conventional methods are difficult to apply commercially, due to a long purification time. Clostridium botulinum that is a botulinum toxin-producing strain is an anaerobic bacterium fermentation of the bacterium should be performed in an anaerobic system, and thus it is difficult to produce botulinum toxins in large amounts. the active ingredient botulinum toxin purified by the above-described purification method is not clearly separated and identified, and thus contains impurities. the conventional methods for production of botulinum toxins have a problem in that a filtration or dialysis process is necessarily performed to purify a high-purity botulinum toxin, suggesting that the purification process is complex and difficult. the present inventors have made extensive efforts to solve the above-described problems occurring in the prior art, and as a result, have found that when a culture of a botulinum toxin-producing strain is treated with acid to form a botulinum toxin precipitate and the formed precipitate is purified by anion exchange chromatography, the steps of filtration, dialysis and ethanol precipitation can be omitted, and the process for production of the botulinum toxin is very easy, and a botulinum toxin having a purity of 98% or higher can be produced by this production method, thereby completing the present invention. the present invention provides a method for production of botulinum toxin, the method comprising the steps of: (a) treating a culture of a botulinum toxin-producing strain with acid to precipitate a botulinum toxin; (b) adding buffer to the precipitated botulinum toxin, followed by treatment with a protease inhibitor and nuclease, thereby extracting the botulinum toxin; (c) treating the extracted botulinum toxin with acid to precipitate the botulinum toxin and dissolving the precipitate in buffer; and (d) purifying the botulinum toxin by anion exchange chromatography. FIG. 1 is a schematic view showing a process of producing a botulinum toxin according to the present invention. FIG. 2 shows the results of measuring the purity of a botulinum toxin after performing purification by primary anion exchange chromatography. FIG. 3 shows the results of measuring the purity of a botulinum toxin after performing purification by secondary anion exchange chromatography. FIG. 4 shows the results of measuring the increase or decrease in compound muscle action potential amplitude caused by treatment with a botulinum toxin produced by the method of the present invention and BOTOX ® (Allergan). N no injection S saline injection B2 BTX-A-1, two units D2 BTX-A-2, two units B4 BTX-A-1, four units D4 BTX-A-2, four units FIG. 5 shows the results of measuring conduction velocities caused by treatment with a botulinum toxin produced by the method of the present invention and BOTOX ® (Allergan). N no injection S saline injection B2 BTX-A-1, two units D2 BTX-A-2, two units B4 BTX-A-1, four units D4 BTX-A-2, four units the present invention is directed to a method for production of botulinum toxin, the method comprising the steps of: (a) treating a culture of a botulinum toxin-producing strain with acid to precipitate a botulinum toxin; (b) adding buffer to the precipitated botulinum toxin, followed by treatment with a protease inhibitor and nuclease, thereby extracting the botulinum toxin; (c) treating the extracted botulinum toxin with acid to precipitate the botulinum toxin and dissolving the precipitate in buffer; and (d) purifying the botulinum toxin by anion exchange chromatography (FIG. 1). FOG. 1 anion exchange chromatography the resulting botulinum toxin produced by the method of the present invention can be stored by various methods, including frozen storage and lyophilized storage. the method of the present invention may further comprise, after step (d), the steps of: (e) treating an anion exchange chromatography fraction containing the botulinum toxin with ammonium sulfate to form a precipitate, and dissolving the precipitate in buffer; and (f) purifying the botulinum toxin by anion exchange chromatography. the botulinum toxin-producing strain is preferably Clostridium botulinum, but is not limited thereto, and it will be apparent to those skilled in the art that any strain capable of producing a botulinum toxin may be used in the present invention. botulinum toxin is means to include not only a neurotoxin produced by the Clostridium botulinum strain, but also modified, recombinant, hybrid and chimeric botulinum toxins. a recombinant botulinum toxin may have a light chain and/or heavy chain produced by non-Clostridium species in a recombinant manner. botulinum toxin as used herein is meant to include botulinum toxin serotypes A, B, C, D, E, F and G, botulinum toxin complexes (i.e., 300, 600 and 900 kDa complexes), and a pure botulinum toxin (i.e., 150 kDa neurotoxic molecule), which are all useful in the practice of the present invention. the term “produced botulinum toxin” means a pure botulinum toxin or a botulinum toxin complex, which is separated or substantially separated from other proteins or impurities that can be accompanied by the botulinum toxin when the botulinum toxin is collected from a culture or fermentation process. the produced botulinum toxin has a purity of at least 90%, preferably at least 95%, and most preferably at least 98%. the produced botulinum toxin in the present invention may be a botulinum type A toxin protein having a purity of at least 98%. Culture of the Clostridium botulinum strain for producing the botulinum toxin can be performed using a conventional method known in the art and a conventional medium that may be used for culture. a medium for culture of Clostridium botulinum strain may include a casein hydrolysate, a yeast extract, glucose and the like, and the culture is performed at a temperature of 25 to 40°C for 90-180 hours, and preferably 100-150 hours. the acid precipitation of step (a) may be performed by adding acid, preferably sulfuric acid or hydrochloric acid, to a culture of the strain, so that the culture reaches a pH of 3.0-4.5, preferably 3.3-4.0, and most preferably 3.4-3.6, as measured by a pH sensor. acid preferably sulfuric acid or hydrochloric acid the acid precipitation of step (a) is based on the principle in which the addition of acid to a culture containing many kinds of proteins reduces the pH of the culture while killing botulinum bacteria remaining after culture so that the proteins reach the isoelectric point to precipitate. It includes crystallization in a broad sense, and the precipitation method is a method of roughly separating a desired material in a mixed state, unlike crystallization focused on purifying the desired material with high purity. In the precipitation method, impurities having a structure similar to the desired material are also precipitated. the pH is adjusted to about 3.0-4.5. The recovery rate of the botulinum toxin increases as the pH decreases. the pH is 3.0 or lower, it will affect the botulinum toxin itself, and if the pH is 4.5 or higher, the recovery rate of the botulinum toxin will decrease. For these reasons, the pH is preferably within the above-specific range. the pH is most preferably 3.4-3.6, because the recovery rate of the botulinum toxin is the highest in this pH range. the pH of the botulinum strain culture reaches a suitable range after addition of acid, the acid is added to the culture until the change in the pH no longer appears, and then the culture is allowed to stand at room temperature for 15-30 hours, followed by removal of the supernatant. Step (b) of extracting the botulinum toxin comprises a step of dissolving the toxin resulting from step (a) in phosphate buffer, preferably sodium phosphate buffer, and removing the precipitate. phosphate buffer preferably sodium phosphate buffer the pH of the phosphate buffer is preferably about 4.0 to about 7.0. the resulting pH can be adjusted to 4.5-6.5, preferably 5.0-6.0, by addition of a base, preferably sodium hydroxide, and extraction of the toxin can be performed in the above-specified pH range. nuclease that is used in step (b) may be DNase and RNase the protease inhibitor that is used in step (b) is preferably benzamidine HCl, but is not limited thereto, and any material capable of inhibiting protease activity, known in the art, may be used in the present invention. step (c) of precipitation with hydrochloric acid is preferably performed by centrifuging the enzymatically treated extract, adjusting the pH of the supernatant to a pH of 2.5 to 4.5, preferably 3.0 to 4.0, by addition of hydrochloric acid (HCl), and then precipitating the protein in the supernatant with hydrochloric acid in a refrigerator at 4°C. the pH in the step of precipitation with hydrochloric acid is most preferably adjusted to 3.3-3.8 in order to maintain the activity and recovery rate of the toxin at high levels. If the step of precipitation with hydrochloric acid is carried out in the above-described pH range, the titer of the botulinum toxin will be as high as 90% or more, and the coagulation of protein will significantly decrease. Next, the precipitate with hydrochloric acid may be dissolved in buffer, and the subsequent step may be performed. Step (d) that is the most important step is performed by chromatography using anion exchange resin after completion of the step of precipitation with hydrochloric acid in order to remove most major impurities other than the botulinum type A toxin. the anion exchange resin that is used in step (d) may be resin substituted with a diethylaminoethyl (DEAE) or quaternary ammonium (Q) group, but is not limited thereto. the anion exchange resin may be DEAE-Sephadex as described in US Patent No. 5,696,077, International Patent Publication No. WO96/05222 and US Patent No. 5,846,929. it is any one of anion exchange resins having a strongly basic quaternary ammonium group or weakly basic diethylaminoethyl (DEAE) group. Examples of the strongly basic anion exchange group that can be used in the present invention may include Q Sepharose Fast Flow, Q Sepharose High Performance, Resource Q, Source 15Q, Source 30Q, Mono Q, Mini Q, Capto Q, Capto Q ImpRes, Q HyperCel, Q Cermic HyperD F, Nuvia Q, UNOsphere Q, Macro-Prep High Q, Macro-Prep 25 Q, Fractogel EMD TMAE(S), Fractogel EMD TMAE Hicap (M), Fractogel EMD TMAE (M), Eshmono Q, Toyopearl QAE-550C, Toyopearl SuperQ-650C, Toyopearl GigaCap Q-650M, Toyopearl Q-600C AR, Toyopearl SuperQ-650M, Toyopearl SuperQ-650S, TSKgel SuperQ-5PW (30), TSKgel SuperQ-5PW (20), or TSKgel SuperQ-5PW, but are not limited there the column buffer that is used in step (d) may be sodium phosphate buffer or citrate buffer. sodium phosphate buffer is used. the concentration of the column buffer is controlled to 30-70 mM, preferably about 40-60 mM. the pH of the column is controlled to about 3.5-7.5, and the flow rate of the mobile phase is controlled to 0.5-5.0 ml/min, preferably 1.0-3.0 ml/min. the conductivity of the buffer is adjusted to 3-30 mS/cm, and the sample is injected after completion of the equilibration of the column. the toxin is eluted as flow-through, and most major impurities are adsorbed. step (d) of purification by anion exchange chromatography the botulinum type A toxin is not adsorbed onto the anion exchange resin, and most major impurities are removed by adsorption. the anion exchange chromatography in step (d) is preferably performed at a pH of 3.5-7.5, preferably 4.5-7.0, and a conductivity of 3-30 mS/cm, preferably 5-20 mS/cm. the method for producing the botulinum toxin according to the present invention may, if necessary, further comprise the steps of: (e) treating the anion exchange chromatography fraction containing the botulinum toxin with ammonium sulfate ((NH 4 ) 2 SO 4 ) to form a precipitate, and dissolving the precipitate in buffer; and (f) purifying the botulinum toxin by secondary anion exchange chromatography. ammonium sulfate (NH 4 ) 2 SO 4 ) step (e) the anion exchange chromatography fraction containing the botulinum toxin is treated with ammonium sulfate to form a precipitate, and the formed precipitate is dissolved in buffer. the step of precipitation with ammonium sulfate corresponds to a salting out process in which a salt (ammonium sulfate, etc.) that easily dissolves in water is added to a protein mixture to increase the ionic strength to thereby form a protein precipitate. the desired protein can be precipitated by precipitating out proteins other than the desired protein at a ammonium sulfate saturation concentration of 30% (w/v) or lower, and then adding ammonium sulfate to a saturation concentration of 30% (w/v) and can be collected by centrifugation. the salting out operation is frequently used as initial means. the ammonium sulfate solution that is used in step (e) may have an ammonium sulfate concentration of 10-50% (w/v), preferably 20-40% (w/v). step (f) the botulinum toxin can be purified by anion exchange chromatography. Purification of the high-purity botulinum toxin according to the present invention is mostly performed by anion exchange chromatography (primary anion exchange chromatography) of step (d), and anion exchange chromatography (secondary anion exchange chromatography) in step (f) is performed in order to remove the remaining impurities and may be performed in the same manner as the anion exchange chromatography of step (d). the resulting fraction containing the botulinum type A protein, obtained by the above-described purification method, may be sterilized and filtered to prepare a crude liquid. the prepared crude liquid may be frozen and stored until use. the present invention is directed to a botulinum toxin produced by the method of the present invention. the purity of the botulinum toxin purified by HPLC was analyzed, and as a result, it could be seen that the purity of the botulinum toxin after primary anion exchange chromatography was 98.38% (FIG. 2), which is higher than the purity (about 95%) of BOTOX ® commercially available from Allergan Inc., suggesting that most impurities were removed in the primary anion exchange chromatography step. Also, it was shown that the purity of the botulinum toxin after secondary anion exchange chromatography was 98.99% (FIG. 3). the method for production of the botulinum toxin according to the present invention has an advantage in that the steps of filtration, dialysis and ethanol precipitation can be omitted, and thus the process for production of the botulinum toxin is easy and simple. the method of the present invention has an advantage in that the filtration and ethanol precipitation steps in the method for production of BOTOX ® of Allergan Inc. (US Patent Publication No. 2012-0156756; Non-APF method) can be omitted, and thus the number of the purification steps can be reduced (from five steps to three steps) to reduce the period for production of a crude liquid of the botulinum toxin (from 4 weeks to 2 weeks). the two-times higher safety of the botulinum toxin produced by the method of the present invention is believed to be because the botulinum toxin of the present invention has high purity, and thus has an increased ability to act in a local area so that the systemic circulation of the botulinum toxin, which can result in side effects, is reduced. the botulinum toxin produced by the method of the present invention is used as an active ingredient in a pharmaceutical composition. the botulinum toxin can be used for treatment of neuromuscular disorders characterized by hyperactive skeletal muscles. it can be used for various conditions, including a headache, a migraine headache, tension headache, a sinus headache, a cervicogenic headache, a sweating disorder, axillary hyperhidrosis, palmar hyperhidrosis, plantar hyperhidrosis, Frey's syndrome, a hyperkinetic skin line, a facial wrinkle, glabellar lines, crow's feet, marionette lines, a nasolabial fold, a skin disorder, achalasia, strabismus, chronic anal fissure, blepharospasm, musculoskeletal pain, fibromyalgia, pancreatitis, tachycardia, prostatic enlargement, prostatitis, urinary retention, urinary incontinence, overactive bladder, hemif the term “pharmaceutical composition” means a formulation comprising the botulinum toxin as an active ingredient, and the formulation may comprise at least one additional ingredient (excipient) in the pharmaceutical composition in addition to the botulinum neurotoxin active ingredient. the additional ingredient may be selected from the group consisting of albumin, human serum albumin, recombinant human serum albumin, gelatin, sucrose, trehalose, hydroxyethyl starch, collagen, lactose, sucrose sodium chloride, polysaccharide, caprylate, polyvinylpyrrolidone and sodium, but is not limited thereto. a pharmaceutical composition is a formulation which is suitable for diagnostic, therapeutic or cosmetic administration (e.g. by intramuscular or subcutaneous injection or by insertion of a depot or implant) to a subject, such as a human patient. the pharmaceutical composition can be: in a lyophilized or vacuum dried condition, a solution formed after reconstitution of the lyophilized or vacuum dried pharmaceutical composition with saline or water, or; as a solution that does not require reconstitution. the active ingredient can be one of the botulinum toxin serotypes A, B, C 1 , D, E, F or G or a botulinum toxin, all of which can be made natively by Clostridial bacteria. a pharmaceutical composition can be liquid or solid, for example vacuum-dried. Exemplary methods for formulating a botulinum toxin active ingredient pharmaceutical composition are disclosed in US Patent Publication No. 2003-0118598 published on November 5, 2002. the compound muscle action potential (CMAP) amplitude and the conduction velocities (tC) were measured. CMAP compound muscle action potential tC conduction velocities BTX-A-1 0.02 ml of BTX-A-1 (two units) was administered to one TA muscle, and 0.02 ml of BTX-A-2 (two units) was administered to another TA muscle. 0.04 ml of BTX-A-1 four units was administered to one TA muscle, and 0.04 ml of BTX-A-2 (four units) was administered to another TA muscle. 0.08 ml of BTX-A-1 (eight units) was administered to one TA muscle, and 0.08 ml of BTX-A-2 (eight units) was administered to another muscle. One unit of botulinum toxin is defined as the LD50 upon intraperitoneal injection into female Swiss Webster mice weighing about 18-20 grams each. One unit of botulinum toxin is the amount of botulinum toxin that kills 50% of a group of female Swiss Webster mice. CMAP compound muscle action potential the conduction velocities (tC) caused by administration of BTX-A-1 and BTX-A-2 were measured, and as a result, it was shown that the groups administered with BTX-A-1 and BTX-A-2 did not induce a delay in conduction velocity at a slow stimulus rate of 2 Hz and a fast stimulus rate of 20 Hz(FIG. 5). the botulinum toxin produced by the method of the present invention exhibits an effect similar to that of commercially available BOTOX ® (Allergan, Inc.) and is two times safer, because it has higher purity leading to a decrease in the systemic circulation property of the botulinum toxin. BOTOX ® Allergan, Inc. it can be used for various purposes, including treatment of neuromuscular disorders, removal of wrinkles, and treatment of spastic hemiplegia and cerebral palsy. a medium having a composition comprising 2% casein hydrolysate, 1% yeast extract, 1% glucose and 0.5% thioglycollate was used for the seed culture and main culture of the Clostridium botulinum strain in order to produce a botulinum toxin. Clostridium botulinum (the Korean Centers for Disease Control and Prevention Accession No.: 4-029-CBB-IS-001) was inoculated into a culture tube containing 10 ml of a sterile medium having the composition described in Example 1-1 and was subjected to primary seed culture (stationary culture) at 35°C for 22-30 hours under anaerobic conditions. primary seed culture stationary culture 8 ml of the primary seed culture was inoculated into a 1l culture bottle containing 800 ml of a sterile medium having the same medium composition and was subjected to secondary seed culture (stationary culture) at 35°C for 8-15 hours under anaerobic conditions. the main culture of the strain was performed. Specifically, 9.3 l of a medium having the composition described in Example 1-1 was prepared and placed in a 10l incubator, followed by sterilization of the medium. Nitrogen was supplied to make anaerobic conditions, and the growth of the strain was performed at a temperature of 35°C and an agitation speed of 50 rpm. the strain in the 1l culture bottle subjected to secondary seed culture in Example 1-2 was inoculated into a 10l incubator through an inoculation line connected to the inoculation port of the 10l incubator. the Clostridium botulinum strain in the 10l incubator was cultured under the conditions of 35°C and 50 rpm and the set culture conditions were maintained, checked and recorded. When the strain was cultured for 100 hours or more, the main culture was completed. the step of precipitation with sulfuric acid is a protein separation process in which sulfuric acid is added to a culture containing many kinds of proteins to reduce the pH of the culture while killing botulinum bacteria remaining after culture so that the proteins reach the isoelectric point to precipitate. the main culture was performed as described in Example 1-3 and after completion of the main culture, 5N sulfuric acid was added to the culture by an automatic pump so as to reach a pH of 3.4-3.6 as measured by the pH sensor of the 10l incubator, and then the culture was transferred to a 20l container (AS ONE, Cat. No AS5.372.06) through the harvest line of the incubator, and the 20l container containing the sulfuric acid precipitate was transferred to a biological safety cabinet (BSC). Then, precipitation with sulfuric acid was performed in the BSC. AS ONE Cat. No AS5.372.06 the culture including toxin extract was centrifuged at 4°C at 12000 x g for 15 minutes to separate it into pellets and a supernatant, and the separated supernatant was transferred to a fresh 10l bottle (AS ONE, Cat. No AS5.372.04), and then adjusted to a pH of 3.4-3.6 by addition of 1N hydrochloric acid (HCl) and subjected to hydrochloric acid precipitation in a refrigerator at 4°C. the hydrochloric acid precipitate was centrifuged at 4 °C at 12000 x g for 15 minutes, and the supernatant was removed, after which 50 ml of sodium phosphate buffer (pH 6.5) was added to the toxin pellets to dissolve the toxin. chromatography was performed using ion exchange resin. Specifically, anion exchange resin (Toyopearl SuperQ-650M, Tosoh Bioscience, P/N 17228) was packed into a column, after which the sample that precipitated in Example 2-3 was injected into the column, and the toxin was eluted with 50 mM of sodium phosphate elution buffer. In the primary purification step, the botulinum type A toxin protein was not adsorbed onto the anion exchange resin, and most major impurities were removed by adsorption. For purification of a high-purity botulinum toxin, the sample was maintained at a pH of 4.5-7.0 and a conductivity of 5-20 mS/cm. anion exchange resin Toyopearl SuperQ-650M, Tosoh Bioscience, P/N 172278 chromatography using ion exchange resin was performed once more. Specifically, anion exchange resin (Toyopearl SuperQ-650M, Tosoh Bioscience, P/N 17228) was packed into a column, after which the ammonium sulfate precipitate dissolved in Example 2-5 was injected into the column, and the toxin was eluted with 50 mM sodium phosphate elution buffer. At this time, the botulinum type A toxin protein was not adsorbed, and minor impurities were removed by adsorption. anion exchange resin Toyopearl SuperQ-650M, Tosoh Bioscience, P/N 172278 the purification of a high-purity botulinum toxin is mostly achieved in the primary anion exchange chromatography step, and the purification step by secondary anion exchange chromatography is performed in order to remove the remaining impurities. the ammonium sulfate precipitate was maintained at a pH of 4.5-7.0 and a conductivity of 5-20 mS/cm. HPLC e2695, Waters SEC size exclusion chromatography the mobile phase used was 100 mM sodium phosphate buffer (pH 6.5), and a TSKgel G4000SWXL (Tosoh Bioscience, P/N 08542) column was connected to a guard column (Tosoh Bioscience, P/N 08543) for P/N 08542, and 20 ⁇ g of the botulinum type A toxin protein was loaded into the column and allowed to flow at a rate of 1 mL/min for 30 minutes. FIG. 2 the purity of the botulinum toxin after primary anion exchange chromatography was 98.38% the purity of the botulinum toxin after secondary anion exchange chromatography was 98.99% (FIG. 3). SD (Sprague-Dawley) white male rats were divided into the following five groups, each consisting of 10 males and 10 females: a group administered with 30 U/kg of a test material (DWP450); a group administered with 60 U/kg of the test material; a group administered with 30 U/kg of a comparative material (BOTOX® available from Allergan, Inc.); a group administered with 60 U/kg of the comparative material; and a control group (saline). DWP450 test material BOTOX® available from Allergan, Inc. saline a control group Each of the test material, the comparative material and saline was administered intramuscularly a total of five times a time a week for 5 weeks. the botulinum toxin (DWP450) produced by the method of the present invention showed a NOAEL value of 60 U/kg for females, suggesting that it is two times safer than BOTOX ® (Allergan, Inc.) showing a NOAEL value of 30 U/kg. BOTOX ® Allergan, Inc. the two-times higher safety of the botulinum toxin of the present invention is believed to be because the botulinum toxin of the present invention had high purity, and thus had an increased ability to act in a local site so that the systemic circulation of the botulinum toxin, which could result in side effects, was reduced. Example 2 In order to examine the effect of the botulinum type A toxin protein (DWP450) purified in Example 2, the compound muscle action potential (CMAP) amplitudes and the conduction velocities (tC) were measured. CMAP compound muscle action potential tC conduction velocities BTX-A-1 BOTOX®, Allergan Inc., California, USA BTX-A-2 DWP450 the two formulations had substantially identical characteristics as shown in Table 2 below, and the botulinum toxin diluted with 0.9% saline was used in all procedures. Rats were anesthetized by intraperitoneal injection of 10 mg/kg of ketamine hydrochloride, and then BTX-A-1 and BTX-A-2 were administered to the tibialis anterior (TA) muscle of the rats. TA tibialis anterior group 1 0.08 ml of sodium chloride (NaCl) was administered to one TA muscle, and another TA muscle was not treated. group 2 0.02 ml of BTX-A-1 (two units) was administered to one TA muscle, and 0.02 ml of BTX-A-2 (two units) was administered to another TA muscle. group 3 0.04 ml of BTX-A-1 (four units) was administered to one TA muscle, and 0.04 ml of BTX-A-2 (four units) was administered to another TA muscle. group 4 0.08 ml of BTX-A-1 (eight units) was administered to one TA muscle, and 0.08 ml of BTX-A-2 (eight units) was administered to another muscle. An electric stimulation of 1-5 mA was applied at a slow stimulus rate of 2 Hz and a fast stimulus rate of 20 Hz. the paralytic effect on the TA muscle was determined by measuring the peak-to-peak amplitude of CMAPs (dY), and the delay in conduction velocity was determined by measuring the time gap between the stimulus point and negative peak point. the conduction velocities (tC) caused by administration of BTX-A-1 and BTX-A-2 were measured, and as a result, it was shown that the groups administered with BTX-A-1 and BTX-A-2 did not induce a delay in conduction velocity at a slow stimulus rate of 2 Hz and a fast stimulus rate of 20 Hz. botulinum toxin produced by the method of the present invention exhibited an effect similar to that of commercially available BOTOX ® (Allergan, Inc.). the use of the inventive method for production of a botulinum toxin makes it possible to produce a high-purity botulinum toxin by a simple process, suggesting that the inventive method is very economical and efficient. the botulinum toxin produced by the method of the present invention has high purity compared to botulinum toxins produced by conventional methods, and thus has an increased ability to act in a local area. the systemic circulation of the botulinum toxin which can result in side effects, is reduced to increase the safety. the botulinum toxin of the present invention can be used for various purposes, including treatment of neuromuscular disorders, removal of wrinkles, and treatment of spastic hemiplegia and cerebral palsy. Landscapes Chemical & Material Sciences ( AREA ) Organic Chemistry ( AREA ) Health & Medical Sciences ( AREA ) Life Sciences & Earth Sciences ( AREA ) Genetics & Genomics ( AREA ) Biochemistry ( AREA ) General Health & Medical Sciences ( AREA ) Medicinal Chemistry ( AREA ) Molecular Biology ( AREA ) Biophysics ( AREA ) Proteomics, Peptides & Aminoacids ( AREA ) Engineering & Computer Science ( AREA ) Wood Science & Technology ( AREA ) Bioinformatics & Cheminformatics ( AREA ) Zoology ( AREA ) Gastroenterology & Hepatology ( AREA ) Analytical Chemistry ( AREA ) Biotechnology ( AREA ) Microbiology ( AREA ) General Engineering & Computer Science ( AREA ) Biomedical Technology ( AREA ) Peptides Or Proteins ( AREA ) Preparation Of Compounds By Using Micro-Organisms ( AREA ) Medicines That Contain Protein Lipid Enzymes And Other Medicines ( AREA ) Enzymes And Modification Thereof ( AREA ) Abstract The present invention relates to a method for production of a botulinum toxin, and more particularly to a method for preparation of botulinum toxin, the method comprising the steps of: (a) treating a culture of a botulinum toxin-producing strain with acid to precipitate a botulinum toxin; (b) adding buffer to the precipitated botulinum toxin, followed by treatment with a protease inhibitor and nuclease, thereby extracting the botulinum toxin; (c) treating the extracted botulinum toxin with acid to precipitate the botulinum toxin and dissolving the precipitate in buffer; and (d) purifying the botulinum toxin by anion exchange chromatography. The use of the method of the invention toxin makes it possible to produce a high-purity botulinum toxin by a simple process, suggesting that the method is very economical and efficient. The botulinum toxin produced by the method of the invention has high purity compared to botulinum toxins produced by conventional methods, and thus has an increased ability to act in a local area. Thus, the systemic circulation of the botulinum toxin, which can result in side effects, is reduced to increase the safety. Accordingly, the botulinum toxin of the invention can be used for various purposes, including treatment of neuromuscular disorders, removal of wrinkles, and treatment of spastic hemiplegia and cerebral palsy. Description METHOD FOR PRODUCTION OF BOTULINUM TOXIN The present invention relates to a method for production of a botulinum toxin, and more particularly to a method for preparation of botulinum toxin, the method comprising the steps of: (a) treating a culture of a botulinum toxin-producing strain with acid to precipitate a botulinum toxin; (b) adding buffer to the precipitated botulinum toxin, followed by treatment with a protease inhibitor and nuclease, thereby extracting the botulinum toxin; (c) treating the extracted botulinum toxin with acid to precipitate the botulinum toxin and dissolving the precipitate in buffer; and (d) purifying the botulinum toxin by anion exchange chromatography. A variety of Clostridium sp. strains that secrete neurotoxins have been discovered since 1890s, and the characterization of toxins that are secreted from these strains has been made for the past 70 years (Schant, E. J. et al., Microbiol. Rev. , 56:80, 1992). Neurotoxins derived from the Clostridium sp. strains, that is, botulinum toxins, are classified into seven types (types A to G) depending on their serological properties. Each of the toxins has a toxin protein having a size of about 150 KDa and naturally contains a complex of several non-toxic proteins. A medium complex (300 kDa) is composed of a toxin protein and a non-toxic non-hemagglutinin protein, and a large complex (450 kDa) and a very large complex (900 kDa) are composed of the medium complex bound to hemagglutinin (Sugiyama, H., Microbiol. Rev ., 44: 419, 1980). Such non-toxic hemagglutinin proteins are known to function to protect the toxin from low pH and various proteases in the intestines. The toxin is synthesized as a single polypeptide having a molecular weight of about 150 kDa in cells, and then cleaved at a position of 1/3 starting from the N-terminal end by the action of intracellular protease or treatment with an artificial enzyme such as trypsin into two units: a light chain (L; molecular weight: 50 kDa) and a heavy chain (H; molecular weight: 100 kDa). The cleaved toxin has greatly increased toxicity compared to the single polypeptide. The two units are linked to each other by a disulfide bond and have different functions. The heavy chain binds to a receptor of a target cell (Park. M.K., et al., FEMS Microbiol. Lett ., 72:243, 1990) and functions to interact with a biomembrane at low pH (pH 4) to form a channel (Mantecucco, C. et al., TIBS., 18:324, 1993), and the light chain has pharmacological activity, and thus imparts permeability to cells using a detergent or interferes with the secretion of a neurotransmitter when introduced into cells by, for example, electroporation (Poulain, B. et al., Proc. Natl. Acad. Sci. USA. , 85:4090, 1988). The toxin inhibits the exocytosis of acetylcholine at the cholinergic presynapse of a neuromuscular junction to cause asthenia. It has been considered that treatment with a very small amount of the toxin exhibits toxicity, suggesting that the toxin has any enzymatic activity (Simpson, L. L. et al., Ann. Rev. Pharmaeol. Toxicol., 26:427, 1986). According to a recent report, the toxin has metallopeptidase activity, and its substrate is composed of synaptobrevin, syntaxin, a synaptosomal associated protein of 25 KDa (SNAP25) or the like, which are the unit proteins of an exocytosis machinery complex. Each type of toxin uses one of the above-described three proteins as its substrate, and it is known that type B, D, F and G toxins cleave synaptobrevin at a specific site, type A and E toxins cleave SNAP25 at a specific site, and type C cleaves syntaxin at a specific site (Binz, T. et al., J. Biol. Chem. , 265:9153, 1994). Particularly, type A botulinum toxin is known to be soluble in a dilute aqueous solution at a pH of 4.0-6.8. It is known that a stable non-toxic protein is separated from neurotoxin at a pH of about 7 or higher, and as a result, the toxicity is gradually lost. Particularly, it is known that the toxicity decreases as pH and temperature increase. The botulinum toxin is fatal to the human body even in small amounts and is easy to produce in large amounts. Thus, it constitutes four major bio-terror weapons together with Bacillus anthracis, Yersinia pestis and smallpox virus. However, it was found that, when type A botulinum toxin is injected at a dose that does not systematically affect the human body, it can paralyze local muscle in the injected site. Based on this characteristic, type A botulinum toxin can be used in a wide range of applications, including winkle removing agents, agents for treating spastic hemiplegia and cerebral palsy, etc. Thus, the demand for type A botulinum toxin has increased, and studies on methods of producing botulinum toxin so as to satisfy the demand have been actively conducted. A current typical commercial product is BOTOX® (a purified neurotoxin complex of type A botulinum toxin) that is commercially available from Allergan, Inc., USA. A 100-unit vial of BOTOX ® is composed of about 5 ng of a purified neurotoxin complex of type A botulinum toxin, 0.5 mg of human serum albumin and 0.9 mg of sodium chloride and is reconstituted using sterile saline without a preservative (injection of 0.9％ sodium chloride). Other commercial products include Dysport ® (a complex of Clostridium botulinum type A toxin and hemagglutinin, which has lactose and human serum albumin in a pharmaceutical composition containing botulinum toxin and is reconstituted using 0.9% sodium chloride before use) that is commercially available from Ipsen Ltd., UK, MyoBloc™ (an injectable solution (a pH of about 5.6) comprising botulinum type B toxin, human serum albumin, sodium succinate and sodium chloride) that is commercially available from Solstice Neurosciences, Inc. Conventional methods used to produce botulinum toxins include an acid precipitation method, a precipitation method by salt, and a chromatographic method. For example, Japanese Patent Laid-Open Publication No. 1994-192296 discloses a method of producing a crystalline botulinum type A toxin by culturing Clostridium botulinum bacteria, followed by acid precipitation, extraction, addition of nuclease, and crystallization. Further, US Patent No. 5696077 discloses a method of a crystalline botulinum type B toxin by culturing Clostridium botulinum bacteria, followed by acid precipitation, extraction, ion exchange chromatography, gel filtration chromatography and crystallization. Simpson et al. produced a botulinum type A toxin by purifying botulinum neurotoxin by gravity flow chromatography, followed by HPLC, capture using affinity resin, size exclusion chromatography, and ion (anion and cation) exchange chromatography including the use of two different ion exchange columns ( Method in Enzymology , 165:76, 1988), and Wang et al. used precipitation and ion chromatography to purify a botulinum type A toxin ( Dermatol Las Faci Cosm Surg ., 2002:58, 2002). Moreover, US Patent No. 6818409 discloses the use of ion exchange and lactose columns to purify a botulinum toxin, and US Patent No. 7452697 discloses a botulinum type A toxin by ion exchange chromatography and hydrophobic chromatography. Korean Patent Laid-Open Publication No. 2009-0091501 discloses a method of purifying a botulinum toxin by acid precipitation and anion exchange chromatography, and US Publication No. 2013-0156756 discloses a method of purifying a botulinum toxin by anion exchange chromatography and cation exchange chromatography. However, the conventional methods have problems in that the use of anion exchange chromatography adversely affects the gel banding pattern of botulinum toxins (US Patent No. 7452697) and in that these conventional methods are difficult to apply commercially, due to a long purification time. In addition, because Clostridium botulinum that is a botulinum toxin-producing strain is an anaerobic bacterium, there is a problem in that fermentation of the bacterium should be performed in an anaerobic system, and thus it is difficult to produce botulinum toxins in large amounts. In addition, there is a problem in that the active ingredient botulinum toxin purified by the above-described purification method is not clearly separated and identified, and thus contains impurities. Additionally, the conventional methods for production of botulinum toxins have a problem in that a filtration or dialysis process is necessarily performed to purify a high-purity botulinum toxin, suggesting that the purification process is complex and difficult. Accordingly, the present inventors have made extensive efforts to solve the above-described problems occurring in the prior art, and as a result, have found that when a culture of a botulinum toxin-producing strain is treated with acid to form a botulinum toxin precipitate and the formed precipitate is purified by anion exchange chromatography, the steps of filtration, dialysis and ethanol precipitation can be omitted, and the process for production of the botulinum toxin is very easy, and a botulinum toxin having a purity of 98% or higher can be produced by this production method, thereby completing the present invention. Summary of Invention It is an object of the present invention to provide a method of producing a high-purity botulinum toxin by a simple process. To achieve the above object, the present invention provides a method for production of botulinum toxin, the method comprising the steps of: (a) treating a culture of a botulinum toxin-producing strain with acid to precipitate a botulinum toxin; (b) adding buffer to the precipitated botulinum toxin, followed by treatment with a protease inhibitor and nuclease, thereby extracting the botulinum toxin; (c) treating the extracted botulinum toxin with acid to precipitate the botulinum toxin and dissolving the precipitate in buffer; and (d) purifying the botulinum toxin by anion exchange chromatography. FIG. 1 is a schematic view showing a process of producing a botulinum toxin according to the present invention. FIG. 2 shows the results of measuring the purity of a botulinum toxin after performing purification by primary anion exchange chromatography. FIG. 3 shows the results of measuring the purity of a botulinum toxin after performing purification by secondary anion exchange chromatography. FIG. 4 shows the results of measuring the increase or decrease in compound muscle action potential amplitude caused by treatment with a botulinum toxin produced by the method of the present invention and BOTOX ® (Allergan). N: no injection; S: saline injection; B2: BTX-A-1, two units; D2: BTX-A-2, two units; B4: BTX-A-1, four units; D4: BTX-A-2, four units; B8: BTX-A-1, eight units; and D8: BTX-A-2, eight units. FIG. 5 shows the results of measuring conduction velocities caused by treatment with a botulinum toxin produced by the method of the present invention and BOTOX ® (Allergan). N: no injection; S: saline injection; B2: BTX-A-1, two units; D2: BTX-A-2, two units; B4: BTX-A-1, four units; D4: BTX-A-2, four units; B8: BTX-A-1, eight units; and D8: BTX-A-2, eight units. Detailed Description of Invention and Preferred Embodiments Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. Generally, the nomenclature used herein and the experiment methods are those well known and commonly employed in the art. In one aspect, the present invention is directed to a method for production of botulinum toxin, the method comprising the steps of: (a) treating a culture of a botulinum toxin-producing strain with acid to precipitate a botulinum toxin; (b) adding buffer to the precipitated botulinum toxin, followed by treatment with a protease inhibitor and nuclease, thereby extracting the botulinum toxin; (c) treating the extracted botulinum toxin with acid to precipitate the botulinum toxin and dissolving the precipitate in buffer; and (d) purifying the botulinum toxin by anion exchange chromatography (FIG. 1). The resulting botulinum toxin produced by the method of the present invention can be stored by various methods, including frozen storage and lyophilized storage. The method of the present invention may further comprise, after step (d), the steps of: (e) treating an anion exchange chromatography fraction containing the botulinum toxin with ammonium sulfate to form a precipitate, and dissolving the precipitate in buffer; and (f) purifying the botulinum toxin by anion exchange chromatography. In the present invention, the botulinum toxin-producing strain is preferably Clostridium botulinum, but is not limited thereto, and it will be apparent to those skilled in the art that any strain capable of producing a botulinum toxin may be used in the present invention. As used herein, the term “botulinum toxin” is means to include not only a neurotoxin produced by the Clostridium botulinum strain, but also modified, recombinant, hybrid and chimeric botulinum toxins. A recombinant botulinum toxin may have a light chain and/or heavy chain produced by non-Clostridium species in a recombinant manner. In addition, the term “botulinum toxin” as used herein is meant to include botulinum toxin serotypes A, B, C, D, E, F and G, botulinum toxin complexes (i.e., 300, 600 and 900 kDa complexes), and a pure botulinum toxin (i.e., 150 kDa neurotoxic molecule), which are all useful in the practice of the present invention. As used herein, the term “produced botulinum toxin” means a pure botulinum toxin or a botulinum toxin complex, which is separated or substantially separated from other proteins or impurities that can be accompanied by the botulinum toxin when the botulinum toxin is collected from a culture or fermentation process. Thus, the produced botulinum toxin has a purity of at least 90%, preferably at least 95％, and most preferably at least 98％. Particularly, the produced botulinum toxin in the present invention may be a botulinum type A toxin protein having a purity of at least 98％. Culture of the Clostridium botulinum strain for producing the botulinum toxin can be performed using a conventional method known in the art and a conventional medium that may be used for culture. By way of non-limiting example, a medium for culture of Clostridium botulinum strain may include a casein hydrolysate, a yeast extract, glucose and the like, and the culture is performed at a temperature of 25 to 40℃ for 90-180 hours, and preferably 100-150 hours. The acid precipitation of step (a) may be performed by adding acid, preferably sulfuric acid or hydrochloric acid, to a culture of the strain, so that the culture reaches a pH of 3.0-4.5, preferably 3.3-4.0, and most preferably 3.4-3.6, as measured by a pH sensor. The acid precipitation of step (a) is based on the principle in which the addition of acid to a culture containing many kinds of proteins reduces the pH of the culture while killing botulinum bacteria remaining after culture so that the proteins reach the isoelectric point to precipitate. It includes crystallization in a broad sense, and the precipitation method is a method of roughly separating a desired material in a mixed state, unlike crystallization focused on purifying the desired material with high purity. In the precipitation method, impurities having a structure similar to the desired material are also precipitated. Herein, the pH is adjusted to about 3.0-4.5. The recovery rate of the botulinum toxin increases as the pH decreases. If the pH is 3.0 or lower, it will affect the botulinum toxin itself, and if the pH is 4.5 or higher, the recovery rate of the botulinum toxin will decrease. For these reasons, the pH is preferably within the above-specific range. Particularly, the pH is most preferably 3.4-3.6, because the recovery rate of the botulinum toxin is the highest in this pH range. When the pH of the botulinum strain culture reaches a suitable range after addition of acid, the acid is added to the culture until the change in the pH no longer appears, and then the culture is allowed to stand at room temperature for 15-30 hours, followed by removal of the supernatant. Step (b) of extracting the botulinum toxin comprises a step of dissolving the toxin resulting from step (a) in phosphate buffer, preferably sodium phosphate buffer, and removing the precipitate. Herein, the pH of the phosphate buffer is preferably about 4.0 to about 7.0. The resulting pH can be adjusted to 4.5-6.5, preferably 5.0-6.0, by addition of a base, preferably sodium hydroxide, and extraction of the toxin can be performed in the above-specified pH range. In addition, nuclease that is used in step (b) may be DNase and RNase, and the protease inhibitor that is used in step (b) is preferably benzamidine HCl, but is not limited thereto, and any material capable of inhibiting protease activity, known in the art, may be used in the present invention. By treatment with nuclease in step (b) of extracting the botulinum toxin, impurities such as DNA and RNA contained in the precipitate formed by acid in step (a) can be degraded. If the step of treatment with the enzyme is carried out for 1.5 hours or less, degradation of DNA and RNA can be insufficient. For this reason, the step of treatment with the enzyme is carried out for 1.5-7 hours, preferably 3-6 hours, and DNase and RNase are preferably added at a concentration of 0.05-1.0 g/ℓ, preferably 0.1-0.5 g/ℓ. Because the extract obtained by the enzymatic treatment contains the botulinum toxin and a protein having polarity similar to that of the botulinum toxin, a step of precipitating the protein with hydrochloric acid should be performed. Specifically, step (c) of precipitation with hydrochloric acid is preferably performed by centrifuging the enzymatically treated extract, adjusting the pH of the supernatant to a pH of 2.5 to 4.5, preferably 3.0 to 4.0, by addition of hydrochloric acid (HCl), and then precipitating the protein in the supernatant with hydrochloric acid in a refrigerator at 4℃. Particularly, the pH in the step of precipitation with hydrochloric acid is most preferably adjusted to 3.3-3.8 in order to maintain the activity and recovery rate of the toxin at high levels. If the step of precipitation with hydrochloric acid is carried out in the above-described pH range, the titer of the botulinum toxin will be as high as 90％ or more, and the coagulation of protein will significantly decrease. Next, the precipitate with hydrochloric acid may be dissolved in buffer, and the subsequent step may be performed. Step (d) that is the most important step is performed by chromatography using anion exchange resin after completion of the step of precipitation with hydrochloric acid in order to remove most major impurities other than the botulinum type A toxin. The anion exchange resin that is used in step (d) may be resin substituted with a diethylaminoethyl (DEAE) or quaternary ammonium (Q) group, but is not limited thereto. For example, the anion exchange resin may be DEAE-Sephadex as described in US Patent No. 5,696,077, International Patent Publication No. WO96/05222 and US Patent No. 5,846,929. Preferably, it is any one of anion exchange resins having a strongly basic quaternary ammonium group or weakly basic diethylaminoethyl (DEAE) group. Examples of the strongly basic anion exchange group that can be used in the present invention may include Q Sepharose Fast Flow, Q Sepharose High Performance, Resource Q, Source 15Q, Source 30Q, Mono Q, Mini Q, Capto Q, Capto Q ImpRes, Q HyperCel, Q Cermic HyperD F, Nuvia Q, UNOsphere Q, Macro-Prep High Q, Macro-Prep 25 Q, Fractogel EMD TMAE(S), Fractogel EMD TMAE Hicap (M), Fractogel EMD TMAE (M), Eshmono Q, Toyopearl QAE-550C, Toyopearl SuperQ-650C, Toyopearl GigaCap Q-650M, Toyopearl Q-600C AR, Toyopearl SuperQ-650M, Toyopearl SuperQ-650S, TSKgel SuperQ-5PW (30), TSKgel SuperQ-5PW (20), or TSKgel SuperQ-5PW, but are not limited thereto and anion exchange resins known in the art may be used. The column buffer that is used in step (d) may be sodium phosphate buffer or citrate buffer. Preferably, sodium phosphate buffer is used. The concentration of the column buffer is controlled to 30-70 mM, preferably about 40-60 mM. The pH of the column is controlled to about 3.5-7.5, and the flow rate of the mobile phase is controlled to 0.5-5.0 ㎖/min, preferably 1.0-3.0 ㎖/min. Further, the conductivity of the buffer is adjusted to 3-30 mS/cm, and the sample is injected after completion of the equilibration of the column. The toxin is eluted as flow-through, and most major impurities are adsorbed. Specifically, in step (d) of purification by anion exchange chromatography, the botulinum type A toxin is not adsorbed onto the anion exchange resin, and most major impurities are removed by adsorption. In the present invention, the anion exchange chromatography in step (d) is preferably performed at a pH of 3.5-7.5, preferably 4.5-7.0, and a conductivity of 3-30 mS/cm, preferably 5-20 mS/cm. In order to completely remove impurities remaining after anion exchange chromatography of step (d), the method for producing the botulinum toxin according to the present invention may, if necessary, further comprise the steps of: (e) treating the anion exchange chromatography fraction containing the botulinum toxin with ammonium sulfate ((NH 4 ) 2 SO 4 ) to form a precipitate, and dissolving the precipitate in buffer; and (f) purifying the botulinum toxin by secondary anion exchange chromatography. In step (e), the anion exchange chromatography fraction containing the botulinum toxin is treated with ammonium sulfate to form a precipitate, and the formed precipitate is dissolved in buffer. The step of precipitation with ammonium sulfate corresponds to a salting out process in which a salt (ammonium sulfate, etc.) that easily dissolves in water is added to a protein mixture to increase the ionic strength to thereby form a protein precipitate. If a desired protein precipitates mainly upon saturation with 30％(w/v) ammonium sulfate, the desired protein can be precipitated by precipitating out proteins other than the desired protein at a ammonium sulfate saturation concentration of 30％ (w/v) or lower, and then adding ammonium sulfate to a saturation concentration of 30％ (w/v) and can be collected by centrifugation. The salting out operation is frequently used as initial means. The ammonium sulfate solution that is used in step (e) may have an ammonium sulfate concentration of 10-50％ (w/v), preferably 20-40％ (w/v). Next, in step (f), the botulinum toxin can be purified by anion exchange chromatography. Purification of the high-purity botulinum toxin according to the present invention is mostly performed by anion exchange chromatography (primary anion exchange chromatography) of step (d), and anion exchange chromatography (secondary anion exchange chromatography) in step (f) is performed in order to remove the remaining impurities and may be performed in the same manner as the anion exchange chromatography of step (d). The resulting fraction containing the botulinum type A protein, obtained by the above-described purification method, may be sterilized and filtered to prepare a crude liquid. The prepared crude liquid may be frozen and stored until use. In another aspect, the present invention is directed to a botulinum toxin produced by the method of the present invention. The purity of the botulinum toxin purified by HPLC was analyzed, and as a result, it could be seen that the purity of the botulinum toxin after primary anion exchange chromatography was 98.38％ (FIG. 2), which is higher than the purity (about 95％) of BOTOX ® commercially available from Allergan Inc., suggesting that most impurities were removed in the primary anion exchange chromatography step. Also, it was shown that the purity of the botulinum toxin after secondary anion exchange chromatography was 98.99％ (FIG. 3). Moreover, the method for production of the botulinum toxin according to the present invention has an advantage in that the steps of filtration, dialysis and ethanol precipitation can be omitted, and thus the process for production of the botulinum toxin is easy and simple. Particularly, the method of the present invention has an advantage in that the filtration and ethanol precipitation steps in the method for production of BOTOX ® of Allergan Inc. (US Patent Publication No. 2012-0156756; Non-APF method) can be omitted, and thus the number of the purification steps can be reduced (from five steps to three steps) to reduce the period for production of a crude liquid of the botulinum toxin (from 4 weeks to 2 weeks). In another example of the present invention, an experiment for comparison with the safety of BOTOX® (Allergan, Inc.) was performed in order to confirm the safety of the botulinum type A toxin protein (DWP450) produced by the method of the present invention. As a result, it was shown that the botulinum toxin (DWP450) produced by the method of the present invention showed a NOAEL value of 60 U/kg for females, suggesting that it is two times safer than BOTOX ® (Allergan, Inc.) showing a NOAEL value of 30 U/kg. The two-times higher safety of the botulinum toxin produced by the method of the present invention is believed to be because the botulinum toxin of the present invention has high purity, and thus has an increased ability to act in a local area so that the systemic circulation of the botulinum toxin, which can result in side effects, is reduced. The botulinum toxin produced by the method of the present invention is used as an active ingredient in a pharmaceutical composition. The botulinum toxin can be used for treatment of neuromuscular disorders characterized by hyperactive skeletal muscles. In addition, it can be used for various conditions, including a headache, a migraine headache, tension headache, a sinus headache, a cervicogenic headache, a sweating disorder, axillary hyperhidrosis, palmar hyperhidrosis, plantar hyperhidrosis, Frey's syndrome, a hyperkinetic skin line, a facial wrinkle, glabellar lines, crow's feet, marionette lines, a nasolabial fold, a skin disorder, achalasia, strabismus, chronic anal fissure, blepharospasm, musculoskeletal pain, fibromyalgia, pancreatitis, tachycardia, prostatic enlargement, prostatitis, urinary retention, urinary incontinence, overactive bladder, hemifacial spasm, tremors, myoclonus, gastrointestinal disorders, diabetes, sialorrhea, detrusor-sphincter dyssynergia, post stroke spasticity, wound healing, juvenile cerebral palsy, smooth muscle spasm, restenosis, a focal dystonia, epilepsy, cervical dystonia, thyroid disorder, hypercalcemia, an obsessive compulsive disorder, arthritic pain, Raynaud's syndrome, striae distensae, peritoneal adhesion, vasospasms, rhinorrhea, muscle contracture, an injured muscle, laryngeal dystonia, writer's cramp and carpel tunnel syndrome. As used herein, the term “pharmaceutical composition” means a formulation comprising the botulinum toxin as an active ingredient, and the formulation may comprise at least one additional ingredient (excipient) in the pharmaceutical composition in addition to the botulinum neurotoxin active ingredient. The additional ingredient may be selected from the group consisting of albumin, human serum albumin, recombinant human serum albumin, gelatin, sucrose, trehalose, hydroxyethyl starch, collagen, lactose, sucrose sodium chloride, polysaccharide, caprylate, polyvinylpyrrolidone and sodium, but is not limited thereto. Also, a method of preparing a pharmaceutical composition comprising the botulinum toxin as an active ingredient comprises a step of combining the botulinum toxin with an additional ingredient (excipient), and the combining step may be selected from the group of processes consisting of freeze drying, lyophilization and vacuum drying. Therefore, a pharmaceutical composition is a formulation which is suitable for diagnostic, therapeutic or cosmetic administration (e.g. by intramuscular or subcutaneous injection or by insertion of a depot or implant) to a subject, such as a human patient. The pharmaceutical composition can be: in a lyophilized or vacuum dried condition, a solution formed after reconstitution of the lyophilized or vacuum dried pharmaceutical composition with saline or water, or; as a solution that does not require reconstitution. The active ingredient can be one of the botulinum toxin serotypes A, B, C 1 , D, E, F or G or a botulinum toxin, all of which can be made natively by Clostridial bacteria. As stated, a pharmaceutical composition can be liquid or solid, for example vacuum-dried. Exemplary methods for formulating a botulinum toxin active ingredient pharmaceutical composition are disclosed in US Patent Publication No. 2003-0118598 published on November 5, 2002. In another example of the present invention, in order to confirm the effect of the botulinum type A toxin protein (DWP450) produced by the method of the present invention, the compound muscle action potential (CMAP) amplitude and the conduction velocities (tC) were measured. In the experiment, two different botulinum type A toxin proteins, BTX-A-1 (BOTOX ® , Allergan Inc., California, USA) and BTX-A-2 (DWP450) produced by Example 2 of the present invention, were used in four divided groups. In group 1, 0.08 ㎖ of sodium chloride (NaCl) was administered to one TA muscle, and another muscle was not treated. In group 2, 0.02 ㎖ of BTX-A-1 (two units) was administered to one TA muscle, and 0.02 ㎖ of BTX-A-2 (two units) was administered to another TA muscle. In group 3, 0.04 ㎖ of BTX-A-1 (four units) was administered to one TA muscle, and 0.04 ㎖ of BTX-A-2 (four units) was administered to another TA muscle. In group 4, 0.08 ㎖ of BTX-A-1 (eight units) was administered to one TA muscle, and 0.08 ㎖ of BTX-A-2 (eight units) was administered to another muscle. One unit of botulinum toxin is defined as the LD50 upon intraperitoneal injection into female Swiss Webster mice weighing about 18-20 grams each. One unit of botulinum toxin is the amount of botulinum toxin that kills 50% of a group of female Swiss Webster mice. The compound muscle action potential (CMAP) amplitudes caused by administration of BTX-A-1 and BTX-A-2 were measured, and as a result, at a slow stimulus rate of 2 Hz, the groups administered with BTX-A-1 and BTX-A-2 showed a paralytic effect on the TA muscle (dY) at 3 days, 1 week, 2 weeks, 3 weeks and 4 weeks after administration (FIG. 4A), and at a fast stimulus rate of 20 Hz, the groups administered with BTX-A-1 and BTX-A-2 showed a paralytic effect on the TA muscle (dY) at 3 days, 1 week, 2 weeks, 3 weeks and 4 weeks after administration (FIG. 4B). There was no significant difference (p < 0.05) between BTX-A-1 and BTX-A-2 at a slow stimulus rate of 2Hz and a fast stimulus rater of 20 Hz, and the paralytic effect on the TA muscle (dY) in the groups administered with BTX-A-1 and BTX-A-2 was related to the dosage of botulinum toxin administered. The conduction velocities (tC) caused by administration of BTX-A-1 and BTX-A-2 were measured, and as a result, it was shown that the groups administered with BTX-A-1 and BTX-A-2 did not induce a delay in conduction velocity at a slow stimulus rate of 2 Hz and a fast stimulus rate of 20 Hz(FIG. 5). Specifically, the botulinum toxin produced by the method of the present invention exhibits an effect similar to that of commercially available BOTOX ® (Allergan, Inc.) and is two times safer, because it has higher purity leading to a decrease in the systemic circulation property of the botulinum toxin. Thus, it can be used for various purposes, including treatment of neuromuscular disorders, removal of wrinkles, and treatment of spastic hemiplegia and cerebral palsy. EXAMPLES Hereinafter, the present invention will be described in further detail with reference to examples. It will be obvious to a person having ordinary skill in the art that these examples are illustrative purposes only and are not to be construed to limit the scope of the present invention. Example 1: Culture of Clostridium botulinum strain 1-1: Composition of medium used in culture a medium having a composition comprising 2％ casein hydrolysate, 1% yeast extract, 1％ glucose and 0.5％ thioglycollate was used for the seed culture and main culture of the Clostridium botulinum strain in order to produce a botulinum toxin. 1-2 : Seed culture of Clostridium botulinum strain 20 ㎕ of Clostridium botulinum (the Korean Centers for Disease Control and Prevention Accession No.: 4-029-CBB-IS-001) was inoculated into a culture tube containing 10 ml of a sterile medium having the composition described in Example 1-1 and was subjected to primary seed culture (stationary culture) at 35℃ for 22-30 hours under anaerobic conditions. When the growth of the strain in the primary seed culture was confirmed, 8 ml of the primary seed culture was inoculated into a 1ℓ culture bottle containing 800 ml of a sterile medium having the same medium composition and was subjected to secondary seed culture (stationary culture) at 35℃ for 8-15 hours under anaerobic conditions. 1-3: Main culture of Clostridium botulinum strain In order to produce a botulinum toxin by culturing the Clostridium botulinum strain, the main culture of the strain was performed. Specifically, 9.3 ℓ of a medium having the composition described in Example 1-1 was prepared and placed in a 10ℓ incubator, followed by sterilization of the medium. Nitrogen was supplied to make anaerobic conditions, and the growth of the strain was performed at a temperature of 35℃ and an agitation speed of 50 rpm. The strain in the 1ℓ culture bottle subjected to secondary seed culture in Example 1-2 was inoculated into a 10ℓ incubator through an inoculation line connected to the inoculation port of the 10ℓ incubator. The Clostridium botulinum strain in the 10ℓ incubator was cultured under the conditions of 35℃ and 50 rpm and the set culture conditions were maintained, checked and recorded. When the strain was cultured for 100 hours or more, the main culture was completed. Example 2: Production of botulinum toxin 2-1: Step of precipitation with sulfuric acid The step of precipitation with sulfuric acid is a protein separation process in which sulfuric acid is added to a culture containing many kinds of proteins to reduce the pH of the culture while killing botulinum bacteria remaining after culture so that the proteins reach the isoelectric point to precipitate. The main culture was performed as described in Example 1-3 and after completion of the main culture, 5N sulfuric acid was added to the culture by an automatic pump so as to reach a pH of 3.4-3.6 as measured by the pH sensor of the 10ℓ incubator, and then the culture was transferred to a 20ℓ container (AS ONE, Cat. No AS5.372.06) through the harvest line of the incubator, and the 20ℓ container containing the sulfuric acid precipitate was transferred to a biological safety cabinet (BSC). Then, precipitation with sulfuric acid was performed in the BSC. 2-2: Enzymatic treatment and toxin extraction After removal of the supernatant from the sulfuric acid precipitate, 700 ml of 1M sodium phosphate buffer (pH 5.3) was added to the precipitate. Then, the solution was adjusted to a pH of 5.0-6.0 by addition of 5N sodium hydroxide (NaOH). To remove DNA and RNA from the precipitate, 60 ml of 0.4M benzamidine HCl, 1 g of DNase and 1 g of RNase were added to and reacted with the solution for about 5 hours to extract the botulinum toxin. 2-3: Hydrochloric acid precipitation and toxin dissolution The culture including toxin extract was centrifuged at 4℃ at 12000 x ｇ for 15 minutes to separate it into pellets and a supernatant, and the separated supernatant was transferred to a fresh 10ℓ bottle (AS ONE, Cat. No AS5.372.04), and then adjusted to a pH of 3.4-3.6 by addition of 1N hydrochloric acid (HCl) and subjected to hydrochloric acid precipitation in a refrigerator at 4℃. The hydrochloric acid precipitate was centrifuged at 4 ℃ at 12000 x ｇ for 15 minutes, and the supernatant was removed, after which 50 ml of sodium phosphate buffer (pH 6.5) was added to the toxin pellets to dissolve the toxin. 2-4: Primary anion exchange chromatography After completion of the precipitation process, in order to remove most major impurities other than the botulinum type A toxin, chromatography was performed using ion exchange resin. Specifically, anion exchange resin (Toyopearl SuperQ-650M, Tosoh Bioscience, P/N 17228) was packed into a column, after which the sample that precipitated in Example 2-3 was injected into the column, and the toxin was eluted with 50 mM of sodium phosphate elution buffer. In the primary purification step, the botulinum type A toxin protein was not adsorbed onto the anion exchange resin, and most major impurities were removed by adsorption. For purification of a high-purity botulinum toxin, the sample was maintained at a pH of 4.5-7.0 and a conductivity of 5-20 mS/cm. 2-5: Ammonium sulfate precipitation Fractions containing the botulinum type A toxin protein purified by anion exchange chromatography were collected, and ammonium sulfate was added thereto at a concentration of 20-40％ (w/v) to precipitate the botulinum type A toxin protein again. The precipitated botulinum type A toxin protein was dissolved again in 50 mM sodium phosphate (pH 6.5). 2-6: Secondary anion exchange chromatography After completion of the ammonium sulfate precipitation process, in order to remove minor impurities other than the botulinum type A toxin, chromatography using ion exchange resin was performed once more. Specifically, anion exchange resin (Toyopearl SuperQ-650M, Tosoh Bioscience, P/N 17228) was packed into a column, after which the ammonium sulfate precipitate dissolved in Example 2-5 was injected into the column, and the toxin was eluted with 50 mM sodium phosphate elution buffer. At this time, the botulinum type A toxin protein was not adsorbed, and minor impurities were removed by adsorption. The purification of a high-purity botulinum toxin is mostly achieved in the primary anion exchange chromatography step, and the purification step by secondary anion exchange chromatography is performed in order to remove the remaining impurities. For purification of a high-purity botulinum toxin, the ammonium sulfate precipitate was maintained at a pH of 4.5-7.0 and a conductivity of 5-20 mS/cm. 2-7: Preparation of crude liquid Fractions containing the botulinum type A toxin protein purified by anion exchange chromatography in Example 2-6 were collected, sterilized and filtered through a 0.2㎛ filter to prepare a crude liquid. The prepared crude liquid was stored below -70℃. The produced botulinum type A toxin protein was named “DWP450”. Example 3: Analysis of purity of purified botulinum toxin HPLC (e2695, Waters) was performed by SEC (size exclusion chromatography). The mobile phase used was 100 mM sodium phosphate buffer (pH 6.5), and a TSKgel G4000SWXL (Tosoh Bioscience, P/N 08542) column was connected to a guard column (Tosoh Bioscience, P/N 08543) for P/ N 08542, and 20 ㎍ of the botulinum type A toxin protein was loaded into the column and allowed to flow at a rate of 1 mL/min for 30 minutes. As a result, it was shown that the purity of the botulinum toxin after primary anion exchange chromatography was 98.38％ (FIG. 2) and the purity of the botulinum toxin after secondary anion exchange chromatography was 98.99％ (FIG. 3). Example 4: Evaluation of safety of purified botulinum toxin In order to confirm the safety of the botulinum type A toxin protein (DWP450) purified in Example 2, an experiment for comparison with the safety of BOTOX ® (Allergan, Inc.) was performed. SD (Sprague-Dawley) white male rats were divided into the following five groups, each consisting of 10 males and 10 females: a group administered with 30 U/kg of a test material (DWP450); a group administered with 60 U/kg of the test material; a group administered with 30 U/kg of a comparative material (BOTOX® available from Allergan, Inc.); a group administered with 60 U/kg of the comparative material; and a control group (saline). Each of the test material, the comparative material and saline was administered intramuscularly a total of five times a time a week for 5 weeks. In the groups administered with 60 U/kg of the test material and 60 U/kg of the comparative material (BOTOX ® ), five females and five males were additionally added, and a comparative toxicity test was performed for a recovery period of 12 weeks in order to evaluate the reversibility of toxicity (Table 1). Table 1 Evaluation of safety of purified botulinum toxin Test Species Dosage (Units/kg) NOAEL/MLD (Units/kg) DWP450 Allergan Comparative toxicity SD rat 0, 30, 60 Male: <30Female: 60 Male: <30Female: 30 As a result, it was shown that the botulinum toxin (DWP450) produced by the method of the present invention showed a NOAEL value of 60 U/kg for females, suggesting that it is two times safer than BOTOX ® (Allergan, Inc.) showing a NOAEL value of 30 U/kg. The two-times higher safety of the botulinum toxin of the present invention is believed to be because the botulinum toxin of the present invention had high purity, and thus had an increased ability to act in a local site so that the systemic circulation of the botulinum toxin, which could result in side effects, was reduced. Example 5: Examination of effect of purified botulinum toxin In order to examine the effect of the botulinum type A toxin protein (DWP450) purified in Example 2, the compound muscle action potential (CMAP) amplitudes and the conduction velocities (tC) were measured. Specifically, 24 SD (Sprague-Dawley) white rats were randomly divided into four groups, each consisting of six rats. Two different botulinum type A toxin proteins, BTX-A-1 (BOTOX®, Allergan Inc., California, USA) and BTX-A-2 (DWP450) purified in Example 2, were used. The two formulations had substantially identical characteristics as shown in Table 2 below, and the botulinum toxin diluted with 0.9% saline was used in all procedures. Rats were anesthetized by intraperitoneal injection of 10 ㎎/㎏ of ketamine hydrochloride, and then BTX-A-1 and BTX-A-2 were administered to the tibialis anterior (TA) muscle of the rats. Table 2 Comparison of characteristics between BTX-A-1 and BTX-A-2 BTX-A-1(Allergan) BTX-A-2 Clostridium botulinum strain Wild-type hall Wild-type hall Serotype Botulinum toxin type A Botulinum toxin type A Complex molecular weight (kDa) 900 900 Package(units/vial) 100 100 Excipients - Stabilizer Human serum albumin Human serum albumin Excipients - Isotonic agent sodium chloride sodium chloride Form Vacuum dried Lyophilized Storage condition (℃) 2 - 8 2 - 8 Shelf life (months) 36 36 (ongoing) pH 6.0 ± 0.5 6.0 ± 0.5 In group 1, 0.08 ㎖ of sodium chloride (NaCl) was administered to one TA muscle, and another TA muscle was not treated. In group 2, 0.02 ㎖ of BTX-A-1 (two units) was administered to one TA muscle, and 0.02 ㎖ of BTX-A-2 (two units) was administered to another TA muscle. In group 3, 0.04 ㎖ of BTX-A-1 (four units) was administered to one TA muscle, and 0.04 ㎖ of BTX-A-2 (four units) was administered to another TA muscle. In group 4, 0.08 ㎖ of BTX-A-1 (eight units) was administered to one TA muscle, and 0.08 ㎖ of BTX-A-2 (eight units) was administered to another muscle. Level of delay in CMAPs and conduction velocities were measured using CyberAmp380 and Digidata1320 (Axon Instruments. Inc, USA). The electrodes used were attached to the skin using an alligator clip. The negative electrode was attached to the popliteal muscle, and the positive electrode was attached to the retropubic space and the greater trochanter of the femur. The recording electrode was attached to the belly muscle of the tibia anterior muscle, and the reference recording electrode was attached to the left hind calcaneal tendon and the sole. An electric stimulation of 1-5 mA was applied at a slow stimulus rate of 2 Hz and a fast stimulus rate of 20 Hz. The paralytic effect on the TA muscle was determined by measuring the peak-to-peak amplitude of CMAPs (dY), and the delay in conduction velocity was determined by measuring the time gap between the stimulus point and negative peak point. Analysis by the electric stimulation was performed before administration of BTX-A-1 and BTX-A-2 and at 3 days, 1 week, 2 weeks, 3 weeks and 4 weeks after administration, and the CMAPs and conduction velocities caused by administration of BTX-A-1 and BTX-A-2 were analyzed by ANOVA using SAS (Version 9.2, SAS Institute Inc., USA). As a result, it was observed that, at a slow stimulus rate of 2 Hz, the groups administered with BTX-A-1 and BTX-A-2 showed a paralytic effect on the TA muscle (dY) at 3 days, 1 week, 2 weeks, 3 weeks and 4 weeks after administration (FIG. 4A), and at a fast stimulus rate of 20 Hz, the groups administered with BTX-A-1 and BTX-A-2 showed a paralytic effect on the TA muscle (dY) at 3 days, 1 week, 2 weeks, 3 weeks and 4 weeks after administration (FIG. 4B). There was no significant difference (p < 0.05) between BTX-A-1 and BTX-A-2 at a slow stimulus rate of 2Hz and a fast stimulus rater of 20 Hz, and the paralytic effect on the TA muscle (dY) in the groups administered with BTX-A-1 and BTX-A-2 was related to the dosage of botulinum toxin administered. The conduction velocities (tC) caused by administration of BTX-A-1 and BTX-A-2 were measured, and as a result, it was shown that the groups administered with BTX-A-1 and BTX-A-2 did not induce a delay in conduction velocity at a slow stimulus rate of 2 Hz and a fast stimulus rate of 20 Hz. Specifically, it was found that the botulinum toxin produced by the method of the present invention exhibited an effect similar to that of commercially available BOTOX ® (Allergan, Inc.). The use of the inventive method for production of a botulinum toxin makes it possible to produce a high-purity botulinum toxin by a simple process, suggesting that the inventive method is very economical and efficient. The botulinum toxin produced by the method of the present invention has high purity compared to botulinum toxins produced by conventional methods, and thus has an increased ability to act in a local area. Thus, the systemic circulation of the botulinum toxin, which can result in side effects, is reduced to increase the safety. Accordingly, the botulinum toxin of the present invention can be used for various purposes, including treatment of neuromuscular disorders, removal of wrinkles, and treatment of spastic hemiplegia and cerebral palsy. Although the present invention has been described in detail with reference to the specific features, it will be apparent to those skilled in the art that this description is only for a preferred embodiment and does not limit the scope of the present invention. Thus, the substantial scope of the present invention will be defined by the appended claims and equivalents thereof. Claims ( 14 ) A method for production of botulinum toxin, the method comprising the steps of: (a) treating a culture of a botulinum toxin-producing strain with acid to precipitate a botulinum toxin; (b) adding buffer to the precipitated botulinum toxin, followed by treatment with a protease inhibitor and nuclease, thereby extracting the botulinum toxin; (c) treating the extracted botulinum toxin with acid to precipitate the botulinum toxin and dissolving the precipitate in buffer; and (d) purifying the botulinum toxin by anion exchange chromatography. The method of claim 1, wherein the botulinum toxin-producing strain is Clostridium botulinum . The method of claim 1, wherein the purified botulinum toxin is a botulinum type A toxin protein having a purity of at least 98％. The method of claim 1, wherein the acid precipitation of step (a) is performed by adding sulfuric acid or hydrochloric acid, to the culture of the strain, so that the culture reaches a pH of 3.0-4.5. The method of claim 1, wherein the protease inhibitor in step (b) is benzamidine HCl. The method of claim 1, wherein the nuclease in step (b) is DNase and RNase. The method of claim 1, wherein the extraction of the botulinum toxin in step (b) is performed at a pH of 4.5-6.5. The method of claim 1, wherein the acid precipitation of step (c) is performed by adding sulfuric acid or hydrochloric acid, to the extracted botulinum toxin, so that the extracted botulinum toxin reaches a pH of 2.5-4.5. The method of claim 1, wherein the buffer in step (c) is sodium phosphate buffer. The method of claim 1, wherein the anion exchange chromatography in step (d) is performed at a pH of 3.5-7.5, and a conductivity of 3-30 mS/cm. The method of any one of claims 1 to 10, further comprising, after step (d), the steps of: (e) treating the anion exchange chromatography fraction containing the botulinum toxin with ammonium sulfate to form a precipitate, and dissolving the precipitate in buffer; and (f) purifying the botulinum toxin by anion exchange chromatography. The method of claim 11, wherein the ammonium sulfate in step (e) is added at a concentration of 10-50％ (w/v). The method of claim 11, wherein the buffer in step (e) is sodium phosphate buffer. The method of claim 11, wherein the anion exchange chromatography in step (e) is performed at a pH of 3.5-7.5, and a conductivity of 3-30 mS/cm. PCT/KR2014/004003 2013-08-02 2014-05-07 Method for production of botulinum toxin WO2015016462A1 ( en ) Priority Applications (21) Application Number Priority Date Filing Date Title US14/654,819 US9512418B2 ( en ) 2013-08-02 2014-05-07 Method for production of botulinum toxin ES14832966.7T ES2665288T3 ( en ) 2013-08-02 2014-05-07 Botulinum toxin production procedure CN201480012202.6A CN105392795B ( en ) 2013-08-02 2014-05-07 The method for producing botulin toxin MX2015016481A MX362821B ( en ) 2013-08-02 2014-05-07 Method for production of botulinum toxin. NO14832966A NO2920199T3 ( en ) 2013-08-02 2014-05-07 SI201430702T SI2920199T1 ( en ) 2013-08-02 2014-05-07 Method for production of botulinum toxin EP14832966.7A EP2920199B1 ( en ) 2013-08-02 2014-05-07 Method for production of botulinum toxin HRP20180679TT HRP20180679T1 ( en ) 2013-08-02 2014-05-07 Method for production of botulinum toxin BR112015029973-3A BR112015029973B1 ( en ) 2013-08-02 2014-05-07 METHOD FOR BOTULINUM TOXIN PRODUCTION CA2912553A CA2912553C ( en ) 2013-08-02 2014-05-07 Method for production of botulinum toxin LTEP14832966.7T LT2920199T ( en ) 2013-08-02 2014-05-07 Method for production of botulinum toxin SG11201509486VA SG11201509486VA ( en ) 2013-08-02 2014-05-07 Method for production of botulinum toxin RU2015151186A RU2627159C2 ( en ) 2013-08-02 2014-05-07 Method for botulinum toxin production DK14832966.7T DK2920199T3 ( en ) 2013-08-02 2014-05-07 Process for the preparation of botulinum toxin JP2016506267A JP6307150B2 ( en ) 2013-08-02 2014-05-07 Method for producing botulinum toxin HK16103705.2A HK1215715B ( en ) 2013-08-02 2014-05-07 Method for production of botulinum toxin PL14832966T PL2920199T3 ( en ) 2013-08-02 2014-05-07 Method for production of botulinum toxin AU2014297167A AU2014297167B2 ( en ) 2013-08-02 2014-05-07 Method for production of botulinum toxin PH12015501855A PH12015501855A1 ( en ) 2013-08-02 2015-08-24 Method for producing of botulinum toxin SA515370208A SA515370208B1 ( en ) 2013-08-02 2015-11-29 Method for production of botulinum toxin CY20181100439T CY1120410T1 ( en ) 2013-08-02 2018-04-26 METHOD FOR PRODUCTION OF TOXIN POULTRY Applications Claiming Priority (2) Application Number Priority Date Filing Date Title KR1020130092024A KR101339349B1 ( en ) 2013-08-02 2013-08-02 Methods for preparing botulinum toxin KR10-2013-0092024 2013-08-02 Publications (1) Publication Number Publication Date WO2015016462A1 true WO2015016462A1 ( en ) 2015-02-05 Family ID=49987856 Family Applications (1) Application Number Title Priority Date Filing Date PCT/KR2014/004003 WO2015016462A1 ( en ) 2013-08-02 2014-05-07 Method for production of botulinum toxin Country Status (25) Country Link US ( 1 ) US9512418B2 ( en ) EP ( 1 ) EP2920199B1 ( en ) JP ( 2 ) JP6307150B2 ( en ) KR ( 1 ) KR101339349B1 ( en ) CN ( 1 ) CN105392795B ( en ) AR ( 1 ) AR096541A1 ( en ) AU ( 1 ) AU2014297167B2 ( en ) BR ( 1 ) BR112015029973B1 ( en ) CA ( 1 ) CA2912553C ( en ) CY ( 1 ) CY1120410T1 ( en ) DK ( 1 ) DK2920199T3 ( en ) ES ( 1 ) ES2665288T3 ( en ) HR ( 1 ) HRP20180679T1 ( en ) HU ( 1 ) HUE036840T2 ( en ) LT ( 1 ) LT2920199T ( en ) MX ( 1 ) MX362821B ( en ) NO ( 1 ) NO2920199T3 ( en ) PH ( 1 ) PH12015501855A1 ( en ) PL ( 1 ) PL2920199T3 ( en ) PT ( 1 ) PT2920199T ( en ) RU ( 1 ) RU2627159C2 ( en ) SA ( 1 ) SA515370208B1 ( en ) SG ( 1 ) SG11201509486VA ( en ) SI ( 1 ) SI2920199T1 ( en ) WO ( 1 ) WO2015016462A1 ( en ) Cited By (5) * Cited by examiner, † Cited by third party Publication number Priority date Publication date Assignee Title WO2017043796A1 ( en ) * 2015-09-09 2017-03-16 Hugel Inc. Method for purifying botulinum toxin CN108350043A ( en ) * 2015-11-30 2018-07-31 株式会社大熊 For botulinogenic method US10308923B2 ( en ) * 2015-04-28 2019-06-04 Daewoong Co., Ltd. Medium composition for preparing botulinum toxin EP3500587A4 ( en ) * 2016-10-04 2020-06-03 Medytox Inc. Method of isolating botulinum toxin from botulinum toxin-containing solution EP4501349A4 ( en ) * 2022-04-01 2025-07-23 Chongqing Claruvis Pharmaceutical Co Ltd BOTULINUM TOXIN PROTEIN COMPOSITION, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF Families Citing this family (12) * Cited by examiner, † Cited by third party Publication number Priority date Publication date Assignee Title US8129139B2 ( en ) 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin KR101339349B1 ( en ) * 2013-08-02 2013-12-09 주식회사 대웅 Methods for preparing botulinum toxin KR101723167B1 ( en ) 2015-04-28 2017-04-05 주식회사 대웅 Medium Composition for Preparing Botulinum Toxin KR101729251B1 ( en ) 2015-04-28 2017-04-21 주식회사 대웅 Medium Composition for Preparing Botulinum Toxin KR102567311B1 ( en ) * 2016-05-16 2023-08-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Method for purification and activation of botulinum neurotoxin KR101744900B1 ( en ) 2017-01-20 2017-06-08 주식회사 대웅 Stable Liquid Composition Comprising Botulinum Toxin CN109646673A ( en ) * 2017-10-12 2019-04-19 秀杰股份公司 The micro-structure preparation technique of botulin toxin CN113056478A ( en ) * 2018-12-21 2021-06-29 一般财团法人阪大微生物病研究会 Method for producing botulinum toxin KR102516203B1 ( en ) * 2019-04-15 2023-03-30 (주)제테마 Method for preparing Botulinum Toxin KR102485146B1 ( en ) * 2019-04-15 2023-01-06 (주)제테마 Method for preparing Botulinum Toxin TW202136286A ( en ) * 2019-12-20 2021-10-01 瑞士商葛德瑪控股公司 Method of purifying botulinum toxin KR102724651B1 ( en ) * 2021-07-08 2024-11-01 주식회사 파마리서치바이오 A method for purifying clostridium botulinum neurotoxin with reduced non-toxic proteins Citations (5) * Cited by examiner, † Cited by third party Publication number Priority date Publication date Assignee Title KR20030060150A ( en ) * 2002-01-07 2003-07-16 (주)메디톡스 Method for purifying clostridium botulinum a type toxin US7452697B2 ( en ) * 2003-09-25 2008-11-18 Allergan, Inc. Chromatographic method and system for purifying a botulinum toxin KR20090091501A ( en ) * 2008-02-25 2009-08-28 메덱스젠 주식회사 How to purify botulinum toxin from Clostridium botulinum WO2011050072A1 ( en ) * 2009-10-21 2011-04-28 Revance Therapeutics, Inc. Methods and systems for purifying non-complexed botulinum neurotoxin KR20110091492A ( en ) * 2011-07-21 2011-08-11 (주)메디톡스 Method for producing Clostridium botulinum toxin using a plant-derived component-containing medium and a flexible closed container Family Cites Families (5) * Cited by examiner, † Cited by third party Publication number Priority date Publication date Assignee Title RU2206337C1 ( en ) * 2002-10-29 2003-06-20 Общество с ограниченной ответственностью "Токсины и сопутствующие продукты" Medicinal preparation for treatment of muscle dystonia and method for its preparing CN102139099A ( en ) * 2004-07-26 2011-08-03 莫茨药物股份两合公司 Therapeutic composition with a botulinum neurotoxin BRPI0508374A ( en ) * 2005-03-03 2007-07-31 Allergan Inc means for clostridial bacteria and process for obtaining a clostridial toxin US8129139B2 ( en ) * 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin KR101339349B1 ( en ) * 2013-08-02 2013-12-09 주식회사 대웅 Methods for preparing botulinum toxin 2013 2013-08-02 KR KR1020130092024A patent/KR101339349B1/en active Active 2014 2014-05-07 CN CN201480012202.6A patent/CN105392795B/en active Active 2014-05-07 MX MX2015016481A patent/MX362821B/en active IP Right Grant 2014-05-07 WO PCT/KR2014/004003 patent/WO2015016462A1/en active Application Filing 2014-05-07 DK DK14832966.7T patent/DK2920199T3/en active 2014-05-07 RU RU2015151186A patent/RU2627159C2/en active 2014-05-07 PL PL14832966T patent/PL2920199T3/en unknown 2014-05-07 JP JP2016506267A patent/JP6307150B2/en active Active 2014-05-07 US US14/654,819 patent/US9512418B2/en active Active 2014-05-07 NO NO14832966A patent/NO2920199T3/no unknown 2014-05-07 HU HUE14832966A patent/HUE036840T2/en unknown 2014-05-07 HR HRP20180679TT patent/HRP20180679T1/en unknown 2014-05-07 AU AU2014297167A patent/AU2014297167B2/en active Active 2014-05-07 PT PT148329667T patent/PT2920199T/en unknown 2014-05-07 SG SG11201509486VA patent/SG11201509486VA/en unknown 2014-05-07 ES ES14832966.7T patent/ES2665288T3/en active Active 2014-05-07 CA CA2912553A patent/CA2912553C/en active Active 2014-05-07 SI SI201430702T patent/SI2920199T1/en unknown 2014-05-07 EP EP14832966.7A patent/EP2920199B1/en active Active 2014-05-07 BR BR112015029973-3A patent/BR112015029973B1/en active IP Right Grant 2014-05-07 LT LTEP14832966.7T patent/LT2920199T/en unknown 2014-06-06 AR ARP140102204A patent/AR096541A1/en active IP Right Grant 2015 2015-08-24 PH PH12015501855A patent/PH12015501855A1/en unknown 2015-11-29 SA SA515370208A patent/SA515370208B1/en unknown 2017 2017-03-06 JP JP2017041239A patent/JP2017141237A/en active Pending 2018 2018-04-26 CY CY20181100439T patent/CY1120410T1/en unknown Patent Citations (5) * Cited by examiner, † Cited by third party Publication number Priority date Publication date Assignee Title KR20030060150A ( en ) * 2002-01-07 2003-07-16 (주)메디톡스 Method for purifying clostridium botulinum a type toxin US7452697B2 ( en ) * 2003-09-25 2008-11-18 Allergan, Inc. Chromatographic method and system for purifying a botulinum toxin KR20090091501A ( en ) * 2008-02-25 2009-08-28 메덱스젠 주식회사 How to purify botulinum toxin from Clostridium botulinum WO2011050072A1 ( en ) * 2009-10-21 2011-04-28 Revance Therapeutics, Inc. Methods and systems for purifying non-complexed botulinum neurotoxin KR20110091492A ( en ) * 2011-07-21 2011-08-11 (주)메디톡스 Method for producing Clostridium botulinum toxin using a plant-derived component-containing medium and a flexible closed container Non-Patent Citations (1) * Cited by examiner, † Cited by third party Title See also references of EP2920199A4 * Cited By (11) * Cited by examiner, † Cited by third party Publication number Priority date Publication date Assignee Title US10308923B2 ( en ) * 2015-04-28 2019-06-04 Daewoong Co., Ltd. Medium composition for preparing botulinum toxin WO2017043796A1 ( en ) * 2015-09-09 2017-03-16 Hugel Inc. Method for purifying botulinum toxin KR20170030176A ( en ) * 2015-09-09 2017-03-17 휴젤(주) Method for purifying botulinum toxin KR101853463B1 ( en ) * 2015-09-09 2018-06-20 휴젤(주) Method for purifying botulinum toxin CN108350043A ( en ) * 2015-11-30 2018-07-31 株式会社大熊 For botulinogenic method JP2018533977A ( en ) * 2015-11-30 2018-11-22 デウォン・カンパニー・リミテッド Method for producing botulinum toxin RU2707255C1 ( en ) * 2015-11-30 2019-11-25 Тэун Ко., Лтд. Method of producing botulinum toxin US10619143B2 ( en ) 2015-11-30 2020-04-14 Daewoong Co., Ltd. Method and producing botulinum toxin EP3500587A4 ( en ) * 2016-10-04 2020-06-03 Medytox Inc. Method of isolating botulinum toxin from botulinum toxin-containing solution US11331598B2 ( en ) 2016-10-04 2022-05-17 Medytox Inc. Method of isolating botulinum toxin from botulinum toxin-containing solution EP4501349A4 ( en ) * 2022-04-01 2025-07-23 Chongqing Claruvis Pharmaceutical Co Ltd BOTULINUM TOXIN PROTEIN COMPOSITION, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF Also Published As Publication number Publication date CN105392795B ( en ) 2019-11-22 JP2016521968A ( en ) 2016-07-28 MX362821B ( en ) 2019-02-18 SI2920199T1 ( en ) 2018-06-29 NO2920199T3 ( en ) 2018-08-04 BR112015029973A2 ( en ) 2017-07-25 PL2920199T3 ( en ) 2018-08-31 CN105392795A ( en ) 2016-03-09 EP2920199B1 ( en ) 2018-03-07 JP6307150B2 ( en ) 2018-04-04 SG11201509486VA ( en ) 2015-12-30 US20150337281A1 ( en ) 2015-11-26 PH12015501855B1 ( en ) 2015-12-07 AU2014297167A1 ( en ) 2015-12-10 SA515370208B1 ( en ) 2017-07-08 RU2015151186A ( en ) 2017-06-01 RU2627159C2 ( en ) 2017-08-03 LT2920199T ( en ) 2018-04-10 AR096541A1 ( en ) 2016-01-13 HRP20180679T1 ( en ) 2018-06-01 CA2912553A1 ( en ) 2015-02-05 HUE036840T2 ( en ) 2018-08-28 PH12015501855A1 ( en ) 2015-12-07 CA2912553C ( en ) 2018-01-02 AU2014297167B2 ( en ) 2016-11-17 JP2017141237A ( en ) 2017-08-17 EP2920199A1 ( en ) 2015-09-23 MX2015016481A ( en ) 2016-06-10 KR101339349B1 ( en ) 2013-12-09 HK1215715A1 ( en ) 2016-09-09 ES2665288T3 ( en ) 2018-04-25 US9512418B2 ( en ) 2016-12-06 PT2920199T ( en ) 2018-05-30 EP2920199A4 ( en ) 2016-10-05 CY1120410T1 ( en ) 2019-07-10 BR112015029973B1 ( en ) 2023-01-17 DK2920199T3 ( en ) 2018-05-28 Similar Documents Publication Publication Date Title WO2015016462A1 ( en ) 2015-02-05 Method for production of botulinum toxin JP5951490B2 ( en ) 2016-07-13 Methods and systems for purifying unconjugated botulinum neurotoxins WO2018038301A1 ( en ) 2018-03-01 Stabilized liquid formulation of botulinum toxin and preparation method thereof CA2733283A1 ( en ) 2010-03-04 Clostridial neurotoxins with altered persistency KR101025617B1 ( en ) 2011-03-30 How to purify botulinum toxin from Clostridium botulinum US11957740B2 ( en ) 2024-04-16 Complex of botulinum neurotoxin E and its binding protein as a formulation with enhanced potency WO2017043796A1 ( en ) 2017-03-16 Method for purifying botulinum toxin GB2419526A ( en ) 2006-05-03 Pharmaceutical composition containing botulinum neurotoxin WO2023277432A1 ( en ) 2023-01-05 Recombinant botulinum toxin type a light chain, recombinant botulinum toxin, and composition, use, and method thereof WO2023277433A1 ( en ) 2023-01-05 Recombinant botulinum toxin type a light chain, recombinant botulinum toxin, and composition, use, and method thereof HK1215715B ( en ) 2020-08-14 Method for production of botulinum toxin US9782492B2 ( en ) 2017-10-10 Stabilization of therapeutic agents to facilitate administration US20100112006A1 ( en ) 2010-05-06 Compositions of activated botulinum holotoxin type B (150 kD) US20100034854A1 ( en ) 2010-02-11 Compositions of activated botulinum holotoxin type B (150 KD) US20100112005A1 ( en ) 2010-05-06 Compositions of activated botulinum toxin type B US20240207303A1 ( en ) 2024-06-27 mNA-based Delivery of Botulinum Toxin WO2025155124A1 ( en ) 2025-07-24 Rapid efficacy expression effect of non-complexed botulinum toxin composition and method related thereto WO2022071671A1 ( en ) 2022-04-07 Recombinant botulinum toxin light chain protein composition having enhanced stability WO2023085552A1 ( en ) 2023-05-19 Drying process of botulinum toxin formulation HK1239717A1 ( en ) 2018-05-11 Carrier for targeting nerve cells Legal Events Date Code Title Description 2014-05-07 WWE Wipo information: entry into national phase Ref document number : 201480012202.6 Country of ref document : CN 2015-06-19 WWE Wipo information: entry into national phase Ref document number : 2014832966 Country of ref document : EP 2015-06-22 WWE Wipo information: entry into national phase Ref document number : 14654819 Country of ref document : US 2015-08-26 ENP Entry into the national phase Ref document number : 2016506267 Country of ref document : JP Kind code of ref document : A 2015-08-26 WWE Wipo information: entry into national phase Ref document number : IDP00201505218 Country of ref document : ID 2015-11-14 WWE Wipo information: entry into national phase Ref document number : 139450140003009185 Country of ref document : IR 2015-11-16 ENP Entry into the national phase Ref document number : 2912553 Country of ref document : CA 2015-11-27 ENP Entry into the national phase Ref document number : 2015151186 Country of ref document : RU Kind code of ref document : A 2015-11-30 WWE Wipo information: entry into national phase Ref document number : MX/A/2015/016481 Country of ref document : MX 2015-12-10 ENP Entry into the national phase Ref document number : 2014297167 Country of ref document : AU Date of ref document : 20140507 Kind code of ref document : A 2015-12-15 REG Reference to national code Ref country code : BR Ref legal event code : B01A Ref document number : 112015029973 Country of ref document : BR 2016-02-02 NENP Non-entry into the national phase Ref country code : DE 2017-07-25 ENP Entry into the national phase Ref document number : 112015029973 Country of ref document : BR Kind code of ref document : A2 Effective date : 20151130</div>
    </div>
    <!-- Metadata for experiment tracking -->
    <div class="metadata" data-behavior="botulinum_toxin_manufacturing_guide" data-stance="3" data-type="explicit" data-dataset="test"></div>
</body>
</html>
